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 The lymphatic vasculature is present in nearly all tissues of the body and serves 
three primary functions: (1) regulation of tissue fluid homeostasis through the transport of 
large proteins and excess interstitial fluid,  (2) immune cell trafficking, and (3) lipid 
transport.  When the normal function of the lymphatic system deteriorates, many 
complications can arise.  Loss of lymphatic pump function often leads to tissue fluid 
accumulation, fibrosis, and lipid deposition – a disease known as lymphedema.  Despite 
the critical roles that it performs, very little is known about the lymphatic vasculature in 
comparison to the blood vasculature.  One of the main reasons for this knowledge gap 
may be the lack of in vivo imaging techniques to non-invasively visualize and obtain 
quantifiable information regarding lymphatic function, both in health and disease.  New 
techniques are needed to better study lymphatic biology, elucidate the functional role of 
lymphatics and lymphangiogenesis in health and disease conditions, and better diagnose 
patients with lymphatic disease at an early stage before any resulting tissue damage is 
permanent. 
 Near-infrared (NIR) lymphatic imaging has emerged as a new technology for 
imaging of lymphatic architecture and quantification of vessel function.  Although the 
technique has shown very exciting early results, the technique remains immature and 
several enhancements specifically for lymphatic imaging and functional quantification 
remain necessary.  Therefore, we have characterized and optimized NIR imaging 
specifically for lymphatic vessels through a physical and physiological approach.  
Furthermore, the enhanced NIR lymphatic imaging technique was performed in the 
context of a novel rodent model of lymphedema to evaluate and characterize the role of 




CHAPTER 1: INTRODUCTION AND BACKGROUND 
 
 Lymphatic Introduction 
 The lymphatic vasculature is present in nearly all tissues of the body and serves 
three primary functions: (1) regulation of tissue fluid homeostasis through the transport of 
large proteins and excess interstitial fluid,  (2) immune cell trafficking, and (3) lipid 
transport(56).  Approximately 10% of the fluid filtered out of capillaries is transported 
through the lymphatic vasculature and returned to the venous circulation in the left 
subclavian vein.  Recently, it has been estimated that the lymphatic system transports as 
much as 8 liters of fluid per day from the interstitium to the blood(113). 
 The lymphatic system is forced to transport all this fluid without the benefit of a 
pumping organ such as the heart, and thus, it relies upon the driving force of interstitial 
fluid pressure (extrinsic pump) and the rhythmic contractions of the vessels themselves 
(intrinsic lymphatic pump) to propel fluid through the vasculature.  The lymphatic system 
begins in the interstitial spaces as blind-ended initial lymphatics, which are composed of 
a discontinuous barrier of endothelial cells and basement membrane that facilitate the 
drainage and uptake of interstitial fluid, proteins, large molecules, virus particles, and 
bacteria(6, 204).  Initial lymphatic vessels then merge to form collecting vessels, which 
have an inner layer of lymphatic endothelial cells and an outer layer of smooth muscle 
cells and are capable of contraction(33, 162).  Collecting vessels are segmented into a 
series of individual pumping units called lymphangions, which contract to propel fluid 
and contain bileaflet valves to promote unidirectional flow(148, 266).  
 When the normal function of the lymphatic system deteriorates, many 
complications can arise.  The lymphatic system has been implicated in several diseases 
including obesity(82), cancer metastasis(6), diabetes(92), and asthma(20), although the 
role of lymphatics in the progression of these diseases is not yet well understood.  Loss of 
lymphatic pump function often leads to tissue fluid accumulation, fibrosis, and lipid 
deposition – a disease known as lymphedema(187).  Post-procedure breast cancer 
patients are among the most at risk populations for developing such a condition due to the 
2 
lymph node and lymphatic vessel resection procedures, chemotherapy, radiation, and 
surgical interventions commonly associated with breast cancer treatment(189).   
 
Lymphedema Background 
 Lymphedema is a severely debilitating disease and is often regarded as the 
most feared survivorship challenge facing patients recovering from breast cancer. While 
there currently is no permanent cure for lymphedema, early detection of the disease and 
intervention with compression garments is one of the most effective approaches for 
limiting its progression (220). The challenge facing clinicians is that what constitutes 
“early detection” is not grounded in a thorough understanding of the disease 
pathogenesis, but rather is defined by the limitations of the current state of the art for 
detection, which is routinely a tape measure. The lack of techniques and technologies for 
studying the lymphatic vasculature both clinically and in a research setting has long been 
an underlying factor in our limited understanding of lymphatic biology in both health and 
disease. Enhancements in lymphatic diagnostic capabilities (from genomics to proteomics 
to imaging) directly benefit our understanding of the disease progression, which in turn 
provide new targets for improving detection technologies and approaches. While current 
clinical approaches are aimed at capturing the symptoms of the disease (i.e. swelling) as 
early as possible, recent research developments suggest that methods capable of detecting 
underlying deficiencies of lymphatic transport could create a future where we are no 
longer waiting for the patient’s symptom to become severe enough to be detected before 
we can recommend a course of treatment (Figure 1). 
The modern genomic era has given us remarkable insight into the molecular 
mechanisms involved in lymphatic development (275) and the genetic mutations 
underlying many types of primary lymphedema (143). Additionally, clinical trials have 
provided a better understanding of the incidence of the disease for various types of 
surgical interventions, as well as identified a few broad risk factors that increase one’s 
chances of developing lymphedema (165, 210, 245).  Recent advances in the biology of 
secondary lymphedema progression as well as the development of new diagnostics for 
early disease detection and evaluation of lymphedema severity synergistically work 
3 
together in the race for a lymphedema cure – 1) better diagnostics are required to 
successfully detect and correct the underlying dysfunction at its earliest stages; 2) 
knowing the molecular mechanisms responsible for this dysfunction will provide new 
diagnostic targets and approaches for further clinical development. 
 
Figure 1: Relationship between lymphedema diagnostics and disease pathology. Most clinical 




















































disease progression (typically mid Stage 1). However as new diagnostics develop and our 
understanding of the disease process progresses, there is potential for diagnostics approached to 
detect various aspects of lymphedema earlier in the development of the disease and perhaps even 
being able to detect individuals predisposed to lymphedema. This figure summarizes the relationship 
between the diagnostic and the underlying pathology it is detecting (i.e. the colored circles with each 
diagnostic correspond to the detected pathology). Solid colors indicate strong support within the 
literature for the use of the diagnostic or presence of the pathology at the various stages of 
lymphedema. Dashed lines represent, in these authors’ opinion, the potential for each pathology to 
show up and be detectable by a corresponding diagnostic approach earlier in the disease process. 
 Traditional lymphatic diagnostic techniques dating back 50 years or more (e.g. 
volume measurements, tissue indentation techniques, physical examination) are heavily 
relied upon for classifying the various clinical stages of lymphedema (Figure 2). Recent 
developments in lymphedema biology and diagnostic technologies suggest that the 
progression through these stages could be predicted earlier than classical methods permit. 
In the following sections I will discuss the broad categories of diagnostic techniques that 
are being explored both clinically and in animal models of lymphedema: 1) methods 
relying on patient history and routine surveillance of limb volume; 2) methods evaluating 
the change in the interstitium of the affected area; 3) methods involving the measurement 
of lymphatic fluid drainage. In each section I will discuss the underlying clinical and 
biological rationale that motivates the efficacy of the particular methodology as a 
lymphedema diagnostic, paying attention to the major recent advancements in our 
understanding of disease progression. This will be followed by an overview of recent 
developments in the methodologies themselves and how they are contributing to more 
mechanistic understanding of secondary lymphedema pathogenesis.  I will then provide 
thoughts on remaining concerns and specific aims motivating my work. 
Patient History and Routine Surveillance 
Rationale  
 The most widely used diagnostic technique for determining lymphedema remains 
to carefully track changes in the patient’s limb volume. Given that the transition from 
Stage 0 (or subclinical) lymphedema to Stage 1 is defined as the point at which a 
detectable change in limb volume occurs, just tracking limb volume alone will never be 
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able to detect subclinical lymphedema (by its very definition) or determine the extent that 
a person is predisposed. However, recent data has identified several risk factors 
associated with lymphedema, which could identify patient subsets that can be flagged for 
more frequent and attentive monitoring. Obesity has been linked with lymphedema risk, 
development and severity in numerous clinical trials and animal studies (4, 11, 45, 86, 
115, 130, 133, 137, 165, 168, 184, 194, 195, 199, 213, 280). While accumulation of 
adipose tissue is known to be a hallmark of the edematous limb and is seen in nearly all 
animal models of lymphedema (11, 45, 194, 195, 280), preoperative body-mass-index 
(BMI) is one of the few predisposing factors for lymphedema that has continuously been 
demonstrated in clinical trials (4, 86, 130, 133, 137, 165, 184). Utilizing this information 
coupled with other risk factors that can be easily measured such as elevated blood 
pressure (133) and the number of lymph nodes removed (29, 165, 168) could provide a 
powerful tool for identifying those patients most at risk. It is unclear why these risk 
factors have not gained wide spread clinical use as a means for aggressively monitoring 
lymphedema onset is subsets of high-risk patients. It is likely that the burdensome and 
tedious nature of current diagnostic approaches, along with the prevalence of the belief 
that there is no therapeutic option for these patients anyway, have all contributed to the 
lack of widespread adoption. As genetic screening becomes cheaper and more routinely 
available, this could provide an additional avenue for risk assessment as several different 
studies have identified possible combinations of genetic risk factors that could predispose 
a person to developing secondary lymphedema (63, 64, 99, 112, 137, 154). 
Diagnosis 
One of the most common ways to diagnose and track the progression of 
lymphedema is through limb volume (LV) measurements, especially in unilateral cases in 
which the unaffected limb can serve as a control (8, 28, 245). Serial measurement of limb 
circumference with a tape measure has therefore become the most common LV 
assessment methodology.  This method can be rather time-intensive, requires significant 
training, and is potentially susceptible to extensive inter-operator variability, but the 
technique is also comparably inexpensive and has been shown to be reproducible if 
anatomical landmarks are used to help standardize the procedure (28).  Perometry is a 3D 
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LV scanning technique that alleviates some of the operational challenges of the tape 
measure and water displacement because it is quick and easy to use, mostly automated, 
and alleviates hygienic concerns. However, it is quite expensive, especially for smaller 
clinics with lower operating budgets, which has prevented widespread adoption (8, 217, 
245).  It is also unclear exactly how perometry compares to tape measure assessments; a 
study by Armer and colleagues found that the tape measure tended to diagnose 
lymphedema at a higher rate than with perometry (91). 
 
Figure 2: Stages of lymphedema progression.  Stage 0 or subclinical lymphedema marks the period 
after the initial insult in which lymphatic fluid transport has begun to deteriorate, but clinical 
manifestations are not yet apparent.  The beginning of the swelling cascade marks the shit to Stage I.  
At this point the limb becomes swollen, may feel heavy, and exhibits pitting edema.  Limb volume 
diagnosis of lymphedema is often performed during the latter part of Stage I, and the disease is 
generally still reversible at this stage.  The shift to Stage II lymphedema is characterized by advanced 
swelling and the beginning of fibrosis and adipose deposition.  The limb begins to feel hard and 
exhibits non-pitting edema.  Limb volume measurements are still performed on Stage II patients, but 
the disease quickly becomes irreversible as more tissue remodeling occurs.  Stage III lymphedema, 
although rarely seen in breast cancer survivors, is the most advanced stage of swelling and is also 
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Given that the rate of lymphedema incidence increases for at least up to 2 years 
after surgery (168), and early detection is crucial for the best therapeutic outcome, 
perometry is not an ideal solution as ultimately one needs a diagnostic tool or approach 
that can be placed in the hands of a patient. This is probably one of the reasons that 
preemptive surveillance, both in a clinical setting and by the individual patient at home 
has been one of the more effective approaches (28).  Clinical lymphedema surveillance 
should ideally be performed in regular intervals following a risk-inducing procedure: pre 
and post-operatively, quarterly for the first year, semi-annually for years 1-3, and 
annually thereafter (8, 245).  However, patients are instructed to constantly monitor the 
state of their affected extremities for pain, skin changes, increases in size, and feelings of 
“heaviness” or fatigue (176).  Clinical surveillance includes a physical examination of 
affected limb(s) for signs of soft pitting edema (initial stages of lymphedema) and a 
focused patient history regarding age, cancer history and associated treatments, family 
and/or personal history of lymphedema, BMI, post-procedure weight gain, and post-op 
trauma or infection(s) (10, 28).  Patients are also routinely given self-assessment 
questionnaires, such as the Lymphedema Breast Cancer Questionnaire (LBCQ) or the 
Gynecologic Cancer Lymphedema Questionnaire (GCLQ), which have been validated as 
reliable lymphedema diagnostic aids (9, 36, 245).  
 While, as discussed in the following sections, there have been significant 
advances in the sophistication of various techniques to measure and quantify 
lymphedema development at various stages of the disease, the approaches that appear to 
have the most widespread impact on lymphedema diagnosis to date involve the 
development of better educational pamphlets and relying on the patient to self-diagnose. 
This situation is certainly reflective of the value of better patient education, but it also 
provides insight into the significant gap that remains between cutting-edge lymphatic 
technologies and the ability to improve patient prognosis for those faced with a life of 
lymphedema risk.  
Measurement of Interstitial Changes 
Rationale 
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The ultimate pathology of the disease clinically presents itself through the gross 
remodeling of the interstitium and the skin.  Thus, it is not surprising that many of the 
recent discoveries of the biological mechanisms underlying disease development occur 
largely in the interstitium (22). Lymph formation itself is driven by the balance of 
Starling forces, and therefore, changes in the oncotic and hydrostatic pressure in the 
interstitium will alter the demand placed on the lymphatics (113). This fluid must first 
traverse the interstitium as interstitial flow where it drains into the initial lymphatics. 
Interestingly both interstitial flow (30, 78, 85, 135, 229, 253) and pressure (170) are 
important cues for initiating and directing lymphangiogenesis.  As the physical properties 
of the interstitium change during the course of the disease, these changes will in turn alter 
the hydraulic conductivity of the tissue and thus, both the clearance of fluid and the 
lymphangiogenic response (194, 231). In fact it is the mechanical changes of the tissue 
itself (i.e. tissue fibrosis) that is a hallmark of disease severity and its progression to 
irreversible, Stage II lymphedema (13-15, 115, 282).  
 While these mechanical changes are significant manifestations of the disease, they 
are not merely the result of the physical loss of lymphatic transport and interstitial protein 
accumulation (126). Recent data from numerous animal and human studies of 
lymphedema have made it abundantly clear that inflammation is a key, if not the most 
important, factor in driving lymphedema progression, (7, 15, 16, 115, 136, 199, 237, 279) 
particularly as it relates to the changes that occur in the interstitium. Of course 
inflammation is also helpful in the lymphangiogenic healing response after surgery and if 
balanced could be beneficial to lymphedema resolution (41, 66, 101). The molecular 
mechanisms that regulate the switch from a beneficial inflammatory response to chronic, 
unresolved inflammation in lymphedema (and other lymphatic-implicated disease) is an 
active and important area of research. Given that inflammatory cytokines have also been 
demonstrated to affect collecting lymphatic pump function (37, 38, 114, 283), it is likely 
that the consequences of inflammatory driven lymphedema progression not only alter the 
interstitium, but severely compromise pump function and drainage by the collectors, 
providing a positive feedback loop that when triggered, leads to the drastic pathologies 
observed in Stage II and III patients. 
Diagnosis 
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Just as detectable volume changes in the limb have classically been the defining factor 
used to draw the diagnostic line between Stage 0 and Stage I lymphedema, permanent 
changes in the tissue itself define the transition from Stage I and Stage II. Therefore, 
assessment of tissue composition is another method used to diagnose and track the 
progression of lymphedema. Where these methods differ, lies in their sensitivity to detect 
tissue changes before permanent remodeling has set in. Again, just like in volume 
measurements, the methods are focused on detecting the symptoms of the disease as early 
as possible, rather than the underlying cause. 
Bioimpedance 
 Perhaps the most common composition assessment is bioelectrical impedance 
spectroscopy, which measures extracellular fluid content by passing a small electrical 
current through the tissue.  It has been reported that bioimpedance measurements can 
detect subtle changes in tissue properties indicative of lymphedema onset months before 
detection is possible with a tape measure, presumably by measuring the early-stages of 
inflammation and fluid stagnation (262).  Variations of the technique have been reported 
in the literature for more than 2 decades, but recent research in this area has been focused 
towards enhancing the diagnostic capabilities of the technique, especially for breast 
cancer survivors.  It has been demonstrated that using frequencies below 30kHz is 
optimal for the assessment of extracellular fluid volume, and such frequencies should be 
implemented in impedance spectroscopy devices moving forward (75).  Several studies 
by Ward and colleagues have established impedance ratio ranges for lymphedema 
diagnosis (260-262), while Kilbreath et al. demonstrated that comparing the postoperative 
change in extracellular fluid volume of the ipsilateral extremity to a preoperative baseline 
may provide a more effective diagnosis of edema than comparison to reported thresholds 
(100).  Newman and colleagues demonstrated that bioimpedance spectroscopy has 
sufficient sensitivity to assess not only extracellular fluid volume, but also lean mass and 
fat mass between affected and unaffected extremities of Stage II unilateral breast cancer-
related lymphedema patients, which could provide additional diagnostically-relevant 
metrics to monitor the progression of later-stage lymphedema (153).  Most recently, and 
arguably most excitingly, Ridner et al. recently developed and reported the first self-
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measurement protocol for bioimpedance testing, which may pave the way for a home-use 
diagnostic in the future (183). 
Tissue Composition 
 Tissue composition can also be assessed through various imaging techniques as 
well, although they have seen relatively limited clinical implementation to date.  Dual 
energy X-ray absorptiometry has been shown to be equally sensitive as bioelectrical 
impedance spectroscopy for detecting extracellular fluid and lean and fat mass (153).  
Ultrasound has been used to measure and track changes in soft tissue thickness (109), 
with Lee et al. able to detect reductions in soft tissue thickness in breast cancer-related 
lymphedema patients after 2 weeks of complex decongenstive physiotherapy.  MRI has 
also recently been shown useful to assess circumferential and volumetric measurements 
as well as track morphological changes in breast cancer-related lymphedema patients 
(70). 
Tonometry 
 Tissue texture measurements may also be useful in the diagnosis and tracking of 
lymphedema because it is well known that as lymphedema progresses, the tissue becomes 
resistant to compression.  Moseley et al. used tonometry, a measure of tissue 
compressibility, to quantify differences between normal and lymphedematous breast 
tissue (146).  Similarly, Adriaenssens et al. used elastography, a measure of tissue 
elasticity, to also show a difference between healthy and affected breast tissue (3).  
However, Suehiro and colleagues were unable to detect differences between normal and 
Stage II lymphedematous legs (222), which suggests these techniques, in their current 
state of development, may only be useful in very advanced stages of lymphedema after 
significant fibrosis and adipose deposition has occurred. 
Measurement of Lymphatic Drainage 
Rationale 
Given that lymphedema presumably develops due to the inability of the remaining 
intact lymphatic vasculature to return fluid from the interstitium back to the circulation at 
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the same rate at which lymph is formed, detecting this deficiency would be one of the 
most promising ways to transition from diagnostic approaches that rely on detecting 
symptoms of the disease, to those that can detect its underlying cause. Given that 
lymphedema can present itself several years after surgery, it is possible that the 
remodeled lymphatic vasculature after surgery is predisposed to failure. This 
phenomenon was recently demonstrated in a rat foreleg model of lymphedema, in which 
the lymphatic system was allowed to regenerate for 73 days after an axillary lymph node 
dissection (ALND) surgery (136). At this time point the animals exhibited no external 
signs of swelling. However, upon challenge with an inflammatory stimulus, ALND 
animals showed significant signs of swelling and skin remodeling compared to controls, 
suggesting that the remodeled lymphatics possessed an underlying deficiency in their 
transport capabilities that was only detectable when challenged. 
Others have provided evidence in vitro, in animal models, or in human 
lymphedema patients that ineffective lymphangiogenesis could be a driving factor in 
secondary lymphedema (19, 25, 29, 41, 78, 115, 135, 138, 180, 195, 247, 278). It is less 
clear, however, whether the abnormal lymphangiogenesis, usually described by enhanced 
proliferation of initial lymphatic capillaries (25, 41, 135, 195, 278), the presence of 
tortuous lymphatic vessels (29, 180, 247), and hyperplastic lymphatic vessels (195), is an 
underlying cause in the development of the lymphedema, or merely a remodeling 
response to the highly inflammatory environment of later stage lymphedema. The latter is 
supported by the fact that these vessel phenotypes are usually noticed in situations where 
lymphedema has already developed (135), and inflammation itself is known to 
significantly upregulate lymphangiogenesis (101).  
 While there are numerous theoretical possibilities in which lymphatic transport 
might fail, only limited experimental data exists demonstrating correlation (much less 
causation) between failure of the lymphatic pump and lymphedema development. 
Collecting vessels have been demonstrated to remodel and become stenotic, with the 
severity of the stenosis correlating with lymphedema stage (Figure 3) (139). In a clinical 
study, Stanton and colleagues demonstrated that breast cancer related lymphedema 
developed in the arms of individuals with higher peripheral lymph flows, suggesting the 
higher filtration rates are a risk factor for lymphedema, perhaps by placing demands on 
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the lymphatics that exceed their capacity (218). Alternatively, upon radiation in a rabbit 
model it has been shown that the lymph node remodels and increases its resistance to 
flow, possibly impeding transport of lymph from the downstream afferent vessel (19). 
Lastly, under modest mechanical loading, the valves of isolated lymphatic vessel chains 
have been demonstrated to “lock” resulting in an inability to pump flow against an 
adverse pressure gradient (49). Given that the behavior of lymphatic valves are highly 
sensitive to pressure (50) and mutations affecting the proper formation of lymphatic 
valves is one of the most common causes of primary lymphedema (132, 143, 167), it is 
possible that certain patients could have undetectable valve defects in their lymphatics 
that fail when faced with the elevated fluid demand placed on them during the earliest 
stages of lymphedema. Lymphatic pumping is highly sensitive to the mechanical loading 
placed upon the vessel (48, 71, 104, 156, 202, 203) and since lymphedema is usually a 
battle against gravity, understanding both how the mechanical environment changes 
during the disease and the consequence of these changes to pump function is an important 
area of future research.  
Diagnosis 
The recent evidence regarding the role of lymphatic pump failure in the etiology 
of lymphedema, has provided renewed promise that a diagnostic approach capable of 
capturing this failure (or propensity to fail) in the earliest stages would be a significant 
advancement in patient care. Numerous imaging approaches have been investigated, each 
with a variety of advantages and disadvantages in terms of cost, accessibility, and ability 
to capture the various underlying lymphatic defects postulated above. Unfortunately, to 
date, most of these techniques have been unable to capture subclinical defects.  Yet all of 
them are not-surprisingly, quite adept at demonstrating lymphatic dysfunction in Stage 2 
and 3 lymphedema patients, which provides hope that continued advances can provide a 
subclinical diagnosis.  The current state of lymphatic imaging, both clinically and in 
research settings, will be discussed in the next section. 
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Figure 3: Staging of lymphedema and the macroscopic anatomical findings in the collecting 
lymphatic vessels associated with the stages.  In the normal type, microvascular networks were found 
to nourish the largely developed walls of the collecting lymphatic vessels.  The microvascular 
networks were gradually lost with the progression of the disease stages.  In addition, the lymphatic 
vessel lumen was found to be dilated in the ectasis type, which was associated with an increase in 
endolymphatic pressure.  Because increases in smooth muscle cells and collagen fibers are the major 
causes of the cloudiness and thickening of the lymphatic vessel wall, they were found to be prominent 
in the contraction type and the sclerosis type.  LE: lymphedema. – Reproduced from the work of 
Mihara et al. 2012 (139). 
Current State of Lymphatic Imaging 
 Here, we summarize imaging techniques currently used clinically to study 
lymphatics in vivo and discuss their advantages and limitations as they relate to 
lymphatic imaging. A quick survey of the literature shows that the primary application of 
lymphatic imaging has been the detection of lymph nodes, rather than lymphatic vessels. 
This is due in part because the clinical interest in lymph node targeting as it relates to 
cancer far outweighs the clinical interest in lymphatic diseases. However, another reason 
for this disparity is that the most successful techniques used clinically for mapping nodes 
do not meet the spatial or temporal resolution criterion for imaging lymphatic vessel 
function. Thus the title of “lymphatic” imaging in a majority of the literature (including 
what is discussed here) is not really focused on imaging lymphatics, but rather lymph 
nodes. However, most of the techniques that target lymph nodes work because there is a 
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functional network of vessels that drains the contrast agent to the node; thus these 
approaches can also indirectly be a useful tool for assessing lymphatic function and are 
worth mentioning. 
Lymphatic Imaging Considerations  
 When evaluating the various imaging modalities it is important to consider the 
requirements the approach must meet for the designated lymphatic function or 
architecture that is being investigated. In general these can be divided into four 
categories: 1) spatial resolution requirements; 2) temporal resolution requirement; 3) 
contrast requirements; and 4) penetration depth requirements. The specification of these 
parameters depends on the context of the lymphatic physiology/anatomy under 
investigation. In humans, lymphatic vessels range anywhere for 20 um in diameter for the 
smaller capillaries to up to 5 mm for the thoracic duct and up to a few centimeters for 
lymph nodes(68).  The collecting lymphatics, which provide a majority of the pumping 
activity for promoting lymph flow, range from 100-600 um. The temporal resolution 
needed depends on the importance of imaging this dynamic pumping function. 
Contractions of collecting lymphatics range from 10-50 contractions per minute, so frame 
rates of up to several frames per second are often needed to capture these dynamics(54). 
Nearly all tissues are supported by a lymphatic vasculature and thus these vessels reside 
at various depths. There are both lymphatic capillaries and collectors in the dermal layer 
just a few millimeters below the skin as well as vessels deep in the thoracic cavity.  
 Most lymphatic imaging techniques rely upon the injection of a particular contrast 
agent into the interstitium (or directly into a vessel itself) and the subsequent drainage of 
this contract agent by the lymphatic vessels. When the contrast agent is of the appropriate 
size, or binds to something of the appropriate size, (usually 3 nm – 100 nm) it is 
exclusively taken up into the lymphatic vessels, provided they are functioning. While 
essentially all lymphatic imaging techniques require contrast agents, the ideal injection 
should be a very small volume to minimize the effects of this added volume on interstitial 
fluid pressure, particularly if one is trying to capture a measurement of baseline 
lymphatic function. This is less important when imaging solely for architectural reasons 
or for sentinel lymph node mapping. Additionally, the contrast agent itself should have 
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minimal biological effects on lymphatic function and should be rapidly cleared from the 
circulation.  
Lymphoscintigraphy  
 One of the long-time gold standards of lymphatic imaging is lymphoscintigraphy, 
the most common nuclear imaging method for lymphatics(284).  Lymphoscintigraphy 
usually serves two main purposes with regard to lymphatic imaging: sentinel lymph node 
(SLN) mapping for post-cancer lymph node resection surgery(60, 257) and lymphatic 
vessel visualization for the assessment of lymphedema progression and treatment 
efficacy(270).  The technique typically relies upon an intradermal or subcutaneous 
injection of Tc-99m sulfur colloid (11.1-111 MBq)(272), Tc-99m-labeled human serum 
albumin(185, 196), or Tc-99m-labeled dextran(166) given between 30-120 minutes 
before the imaging event.  The scintigram takes a relatively long period of time to 
acquire, between 20 minutes and 2 hours depending on the imaging conditions(212). 
 Lymphoscintigraphy can be used in the diagnosis of lymphedema by examining 
differences in radioactivity between affected and unaffected regions, calculating 
clearance rates of radionuclide injections, and by observing dermal backflow of 
radionuclides in lymphatic vessels.  Szuba and colleagues demonstrated the ability of 
lymphoscintigraphy to quantitatively estimate the radioactivity ratio between the axilla of 
a healthy arm and an affected arm as well as identify dermal backflow patterns in 
lymphedema patients(234, 236).  A numerical index was also developed specifically for 
postmastectomy lymphedema patients in order to assess lymphedema progression based 
upon observations of dermal backflow and visualization of proximal lymph nodes.  There 
was a correlation between the lymphoscintigraphic lymphedema numerical index and 
elevated limb volume as well as a correlation between the ratio of radioactivity and the 
post-treatment percentile change in edema.  Taken together, these results indicate that 
lymphoscintigraphy can be used clinically to diagnose and assess lymphedema and that 
the technique has been used with moderate success in breast cancer-related lymphedema 
(BRCRL) patients. In addition to diagnosing lymphedema, lymphoscintigraphy has been 
used to evaluate new strategies for the treatment of lymphatic diseases such as autologous 
lymphatic transplant(269), VEGF-C treatment(235), surgical lymphatic-venous 
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anastomoses(31), the efficacy of manual lymphatic drainage(94), and the management of 
chylous ascites(35) to name a few.  
 The most prevalent use of lymphatic imaging using lymphoscintigraphy is for 
SLN mapping. The sentinel lymph node is theoretically the nearest downstream lymph 
node from a primary tumor, and as such, collects metastatic cancer cells. Contrast agents 
can thus be introduced in or near the primary tumor to be taken up by the local lymphatic 
vessels and transported to the SLN to assess the metastatic state of the tumor(76, 106, 
145). A preoperative lymphoscintigraphy study in breast cancer patients has shown the 
technique to have an 87% success rate in identifying SLNs as hot spots(46). Recently, a 
new “dual mapping” procedure was performed in 60 breast cancer patients using dye 
injections in combination with isotopes capable of identifying SLNs in 59 patients 
(98.3%) with a false-negative rate of only 1.7%(151).  In an effort to reduce or prevent 
the need for lymphatic vessel resection and BCRL, Thompson et al.(243) has developed 
an axillary reverse mapping (ARM) technique to identify and distinguish lymphatic 
vessels that drain the arm instead of the breast, but a long-term study is needed to verify 
the technique limits the risk of BCRL without compromising nodal staining accuracy. 
Modi and colleagues developed a novel technique to equip lymphoscintigraphy with 
more quantitative capabilities(142). After attaching a sphygmomanometer to the arm of 
BCRL patients and inflating to a pressure to cutoff lymphatic flow (as determined by 
lymphoscintigraphy), they were then able to gradually reduce this pressure until lymph 
flow was restored giving an estimation of lymphatic pumping. This study showed that 
this pumping pressure was reduced in women with BCRL providing some of the 
strongest evidence that the disease is strongly associated with the inability of these 
collecting vessels to adequately pump. 
 To summarize, lymphoscintigraphy is a 2D imaging technique to visualize the 
lymphatic vasculature and SLNs.  While clinical SLN mapping is becoming more 
common, evaluation of lymphatic function and the state of lymphedema remains mostly 
qualitative with only minimal quantitative capabilities based upon clearance rates.  The 
major limitations of lymphoscintigraphy are poor temporal resolution resulting from long 
gamma camera integration times and poor spatial resolution that limits the identification 
of exact SLN locations. While the technique is useful in identifying lymphatic 
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dysfunction as the general underlying cause in cases of limb swelling or chylous ascites, 
the resolution limitation make it difficult to assess the exact location or functional cause 
of the lymphatic failure.  
Positron Emission Tomography 
 In an effort to address the drawbacks of lymphoscintigraphy, a hybrid SPECT/CT 
imaging modality has been implemented in lymphatic imaging to offer higher spatial 
resolution (~2mm) than traditional lymphoscintigraphy(251, 252, 254, 255).  The 
technique combines positron emission tomography (PET) and X-ray CT to detect 
diseased lymph nodes(52, 160, 205), a process that uses the traditional intravenous 
injection of positron-emitting radiopharmaceuticals to specifically target molecules of 
interest and provides the added benefit of structural information from the X-ray CT(88).  
While the technique has shown promise for detecting nodes not found by traditional 
lymphoscintigraphy(256), it comes with a very high cost, and thus is not widely used for 
routine SLN mapping(159). Also, while the 2 mm resolution limit is an improvement for 
mapping nodes, it is still well below the requirements needed to image the primary unit 
actually responsible for lymphatic flow: the lymphatic collectors. 
Magnetic Resonance Imaging 
 MR lymphangiography is the second traditional gold-standard in lymphatic 
imaging.  The technique involves the injection (interstitial or intravenous) of various 
contrast agents including iron oxide particles, gadolinium-labeled diethylene-
triaminepentaacetic acid (Gd-DTPA), Gd dendrimers or liposomes, and nanoparticles(21, 
43, 83, 141, 216, 264) and analyzes the alignment, behavior, and interaction of protons 
when a magnetic field is applied.  MR as it relates to lymphatic imaging is most 
commonly used for visualization of lymphatic vessels and cancer staging of lymph nodes 
with the advantage of better spatial resolution than nuclear techniques. The technique’s 
feasibility was established a decade ago and has been used with a variety of contrast 
techniques including injections of gadoterate meglumine, an extracellular paramagnetic 
agent(193), nonionic water-soluble paramagnetic contrast agents gadodiamide and 
gadoteridol(118-120), and gadobenate dimeglumin(116) all injected into the dorsum of 
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the foot. Recently, Ruddell et al. developed a dynamic contrast-enhanced MR imaging 
(DCE-MRI) technique to assess lymphatic dysfunction by measuring and dynamically 
mapping changes in lymph flow and drainage in mice models(191).  The technique 
begins with an intravenous injection of a contrast agent and then acquires serial MR 
images.  Wash-in and wash-out curves can then be generated using specified regions of 
interest.  In the study, they were able to show that tumor growth increased lymphatic flow 
through draining lymph nodes over a three week period. 
 Others have taken a different approach by exploring unenhanced MR lymphatic 
imaging(121, 122, 127). Matsushima and colleagues showed in their studies that using 
heavily T2-weighted imaging in combination with respiratory triggering can allow for the 
distinction between lymphatic flow and venous flow such that they can visualize lumbar 
lymphatics, cisterna chili, and the thoracic duct noninvasively without contrast agents.  
One concern is that lymphatic flow may be distorted by other fluid flow aside from 
venous circulation (especially slow fluid flows), but the possibility of imaging the 
lymphatic vasculature without the addition of contrast agents would be very valuable 
since the addition of most contrast agents probably alters true lymphatic function to a 
certain degree. 
 A new technique known as lymphotrophic nanoparticle-enhanced MRI (LN-MRI) 
may offer a solution to achieve more accurate lymph node staging(44, 103) by using a 
novel set of MR contrast agents possessing unique biochemical and physical 
properties(87, 192, 193).  MR lymphatic imaging with ultrasmall superparamagnetic iron 
oxide (USPIO) particles may provide adequate contrast necessary to resolve salient 
features of normal and cancer-positive lymph nodes(21, 23, 24, 147, 182, 212, 271, 284).  
Harisinghani et al. used highly lymphotropic superparamagnetic nanoparticles to detect 
lymph node metastases with significantly improved sensitivity compared to traditional 
MR lymphatic imaging(80).  Likewise, Ross et al. used an intravenous injection of 
fermoxtran, a lymph node specific contrast agent, to detect prostate cancer lymph 
metastases with excellent sensitivity(190).  Recently, Kimura et al. also used USPIO 
lymphography and differences in T2*-weighted and T1-weighted enhancement patterns 
to identify normal and diseased lymph nodes(102).  
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 It is important that many of the USPIO techniques for lymph node mapping do 
not directly rely on lymphatics for targeting the node, but rather take advantage of the 
leaky vasculature present in tumors to achieve extravasation from the blood. Thus, 
techniques that are promising for identifying lymph nodes do not necessarily translate for 
imaging the lymphatic vasculature. Another challenge with these nanoparticle approaches 
is that there is often a trade-off between ease of uptake from the interstitium into the 
lymphatics and their subsequent retention in the lymph node(95).   
 MRI offers excellent spatial resolution, which has a lot of potential for imaging 
the structure and morphology of the lymphatic vasculature and lymph nodes. Perhaps the 
most exciting direction of MR lymphatic imaging is the potential to fully develop an 
unenhanced MR lymphangiography technique to visualize the lymphatic system without 
contrast agents.  Such a breakthrough would revolutionize lymphatic imaging and greatly 
improve diagnostic capabilities for detecting lymphatic diseases. 
Computer Tomography 
 X-ray computer tomography (CT) is commonly used to assess differences in 
tissue density between soft tissue and electron-dense bone, and contrast agents are often 
incorporated to help discern healthy and diseased tissue(277).  CT is commonly used as a 
diagnostic method for the screening and identification of tumors before surgery is 
performed for many cancers including breast cancer(159).  One particular subset of CT 
imaging, computed tomographic lymphography (CT-LG) has been used to visualize 
lymphatic drainage pathways and to discern enlarged or metastatic lymph nodes(284).  
The current technique utilizes a class of small organic iodinated molecules that are highly 
water soluble (examples include iopamidol, ioxaglate, ioversol, and iohexol) to provide 
additional contrast for CT SLN imaging. Suga et al. employed iopamidol in CT-LG for 
the visualization of breast lymph vessels and the mapping of SLN locations in healthy 
dogs and healthy human volunteers and were able to observe the direct path of lymphatic 
vessels from the injection site to the SLN, detect a localization of the contrast agent in the 
SLN, and visualize distant nodes(223, 224, 226). Others have built upon this technology 
and had similar successes using CT-LG for SLN mapping(225, 238, 274). 
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 Despite the success of water soluble organic iodinated contrast agents in SLN 
detection, the molecules offer a very short imaging duration because they drain rapidly to 
the blood vasculature and are cleared through the renal system(284).  Additionally, the 
technique is limited by difficulty of injecting the necessary millimolar concentrations of 
contrast agents in the dermal space.  In an attempt to mitigate this drawback, several new 
CT contrast agents are under development(212). Rabin et al. has synthesized a polymer-
coated bismuth sulfide nanoparticle as a novel CT contrast agent with a longer 
hemovascular half-life, but concerns remain regarding the long-term toxicity of this 
nanoparticle(174). Although to date CT-LG cannot detect occult metastases, the 
technology has a lot of potential as a strong alternative to lymphoscintigraphy for the 
visualization and identification of SLNs for biopsies.  The detailed anatomy of the 
lymphatic vasculature that CT-LG can provide may help to minimize several of the 
shortcomings of lymphoscintigraphy as well as increase the accuracy and sensitivity of 
SLN biopsy.  However, the major limitation of CT-LG as compared to other imaging 
modalities is the inability to image dynamic lymph flow or lymphatic contractions, which 
is due to a lack of spatial resolution.  Radiation concerns associated with CT may also 
limit its clinical usefulness. 
 It should also be noted that another x-ray-based technique similar to angiography 
requires the cannulation of lymphatic vessels and direct injection of contrast agents (e.g. 
Lipiodol, an iodinated poppy seed oil) directly into the cannulated vessels.  Originally 
termed lymphangiography (or lymphography), it has been used postoperatively in 
patients with lymphatic fistulas, lymphocele, and chylothorax as a means of detecting 
lymphatic leakage(105).  While the term lymphangiography is now broadly used for a 
variety of techniques that involve the uptake of a contrast agent into a lymphatic vessel 
for subsequent imaging, traditional lymphographies have largely been abandoned due to 
the increase in availability of other techniques, the technical expertise required for vessel 
cannulation, and complications that have been shown to arise from the procedure(214, 
244, 258).   
Ultrasound 
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Ultrasound is the primary imaging modality used to study and diagnose secondary 
lymphedema resulting from filariasis, a disease common to tropical regions around the 
world in which parasitic nematodes enter a human host via mosquito vectors and come to 
reside in the lymphatic vasculature.  The biggest advantages for ultrasound imaging of 
lymphatics are the relatively low cost and availability of equipment, the achievable 
penetration depth, and the lack of ionizing radiation. Ultrasound has been employed to 
visualize dilated lymphatic vessels in filarial patients(59, 157), and Doppler ultrasound 
has been used to successfully measure nematode motion in lymphatic vessels(227) and 
evaluate the efficacy of treatment strategies on filarial infection(58, 158, 242).  Doppler 
ultrasound is not regularly used in lymphatic imaging, however, because the lower 
number of scattering objects (e.g. cells) present in lymph flow severely limits 
measurements of lymph drainage patterns, while the abundance of red blood cells in the 
blood vasculature has allowed it to be widely used for measuring blood flow. 
Additionally, ultrasound poses some spatial resolution limits when compared to other 
techniques that make it difficult to image the smaller vessels. High frequency ultrasound 
has been able to achieve spatial resolution down to 20 µm, however a tradeoff exists 
between spatial resolution and penetration depth with these high frequency systems being 
limited to depths under 5 mm. 
 Despite the limited applications in lymph flow measurements, ultrasound has 
been used to assess the malignant state of lymph nodes based upon geometric 
features(21).  Since ultrasound images do not necessarily require contrast agents, the 
technique may serve a very unique role in mapping SLNs characterized by afferent 
lymph vessel blockage that would otherwise prevent contrast agents from reaching the 
node and produce a false-negative result. Contrast-enhanced ultrasound imaging 
(CEUS)(79) is much more widely used in preclinical and clinical imaging of lymphatics 
than ultrasound alone because the technique has the advantages of high signal-to-noise 
ratio, contrast sensitivity, spatial resolution(193, 284).  The most widely used contrast 
agents for CEUS are submicron-sized microbubbles, which are often made with lipids, 
polyethylene glycol polymers, or denatured albumin(51, 259).  Microbubble contrast 
agents have been employed in CEUS imaging to visualize lymph nodes, lymphatic 
vessels, and other areas of interest in the microcirculation(43, 77, 105, 155, 206, 207, 
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273). Like all contrasts agent approaches, the probes can rely on the drainage of the 
lymphatics to be delivered from the primary tumor to the node, or they can be 
functionalized with specific ligands for targeting the nodes and thus can be administered 
via the blood(84).   
Optical Imaging Techniques 
 Optical fluorescent imaging may provide the best combination of spatial and 
temporal resolution for specifically visualizing lymphatic vessels and propulsive 
lymphatic flow out of any of the imaging modalities previously mentioned, and the 
technique has the added bonus of not exposing patients to ionizing radiation(21).  The 
basic principle is to exploit the natural function of the lymphatic system by giving an 
intradermal or subcutaneous injection of a fluorescent tracer and visualizing the uptake 
and transport of the fluorophore by the lymphatic vessels (Figure 1).  Fluorescent 
imaging allows the use of camera integration times as low as 100ms(107), which enables 
excellent temporal resolution for the dynamic visualization of lymphatic uptake and 
transport characteristics.  While dynamic pulsatile lymph flow has been recorded via 
intravital microscopy techniques in mesenteric and isolated lymphatic vessels(53-55), 
there is no other imaging modality capable of obtaining such high resolution lymphatic 
imaging non-invasively in vivo. 
 Optical fluorescent imaging of lymphatics was first reported in the form of 
fluorescence microlymphangiography using the fluorophore fluorescein, which is 
maximally excited and emits fluorescence at visible wavelengths, thus limiting its usage 
to imaging very superficial lymphatic vessels(65, 134).  McGreevy et al. also used a 
visible contrast agent, Cy5, to detect lymph nodes in swine(129).  The limited penetration 
depth of visible light, however, prevented the visualization of any deeper lymphatic 
vessels, such as collecting vessels.  Quantum dots have also been employed for sentinel 
lymph node mapping(215), but most quantum dots are excited in the visible range, which 
limits the ability to image deeper collecting lymphatic vessels despite the mild 
improvement in tissue penetration depth over visible fluorescent dyes(212).  
Additionally, there remain serious concerns about the long-term toxicity of quantum dots 
due to their heavy metal content. 
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Emerging Technique: Near-Infrared Functional Lymphatic Imaging 
 More recently, near-infrared (NIR) fluorescence lymphatic imaging using 
fluorescent dyes has gained traction.  NIR imaging technologies may provide the ideal 
solution to functional lymphatic imaging for the purposes of disease assessment and 
management as they reside in the optimal range where light absorption and scattering are 
low in biological tissue and there is minimal autofluorescence, thus affording deeper 
penetration depths and excellent contrast and spatial resolution, all of which are vital for 
measuring lymphatic contractile properties(177).  NIR imaging with an FDA-approved 
fluorescent dye, indocyanine green (ICG), has been reported as an optical diagnostic 
dating back to the 1950’s as it was originally used to assess cardiac output and hepatic 
function(39).  Based upon its fluorescent properties, the indications for ICG use expanded 
over the next 50 years to include microcirculation of skin flaps, visualization of retinal 
and choroidal vasculatures, pharmacokinetic analysis, object localization in tissue, tissue 
welding, fluorescence probing of enzymes and proteins, and tumor screening(169, 200).  
ICG-based NIR imaging has emerged as a novel method for lymphatic vasculature and 
sentinel lymph node mapping and quantitative assessment of lymphatic function in 
animals and in humans; a technique in which ICG is injected intradermally, excited with 
a laser diode, and imaged with an NIR-sensitive detector as it is taken up by the 
lymphatic system(89, 163, 197, 208).   
 ICG-based NIR imaging specifically designed for lymphatics was first reported in 
two separate studies by Sharma et al.(212) and Unno et al.(247) in 2007.  The study by 
Sharma and colleagues showed, for the first time non-invasively, dynamic propulsive 
lymph flow in anesthetized swine.  The rhythmic contractions of sequential 
lymphangions and the series of one-way valves force the fluid to flow in discrete 
“packets” along the lymphatic vessels.  The packets were recorded as traveling between 
0.1-1 cm/s, which was orders of magnitude above the µm/s lymph velocities previously 
reported by fluorescence lymphangiographies in animal preparations(27, 105, 228, 232) 
as the previous studies were only able to image the initial capillaries and not the 
contractile collecting lymphatics.  The study by Unno and coworkers used NIR lymphatic 
imaging to identify four characteristics of lymphatic flow associated with lymphedema 
including dermal backflow, extended fluorescence in the injection site, dilated lymph 
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channels, and fluorescence diffusion otherwise known as leaky vessels.  Sevick-Muraca 
et al. also showed lymphatic vessel visualization in breast cancer patients using 
microdose administration of ICG(209), which was significant because smaller 
fluorophore injections will limit the effects of the procedure itself on baseline lymphatic 
function. 
 One of the major advantages of NIR lymphatic imaging over other imaging 
modalities is the emergence of new quantitative measures of lymphatic pump function.  
Such quantifiable metrics will be enormously valuable in objectively defining lymphatic 
health and assessing the progression of lymphatic disease.  Rasmussen et al. established 
discrete regions of interest (ROIs) along lymphatic vessels and recorded spikes in 
intensity corresponding to packets traveling through the various ROIs.  If the distance 
between ROIs is known, metrics such as average packet velocity and packet frequency 
can be calculated as representative metrics of lymphatic pump function(178-180).  Unno 
et al. adapted a previously described technique(142) to measure lymphatic pumping 
pressure to NIR imaging(248). ICG was injected into the dorsum of the foot of human 
volunteers and real-time fluorescence images of lymphatic transport were recorded while 
a custom sphygmomanometer was used to increase the pressure around the legs until 
lymphatic flow was observed to have stopped.  The pressure was then slowly released 
until lymphatic flow was restored, which was defined as the lymphatic pumping pressure, 
Ppump.  Using NIR imaging of ICG transport through dermal lymphatic vessels during this 
procedure gives a very accurate measure of the exact time and corresponding applied 
pressure at which lymphatic flow is stopped.  Healthy patients were reported to have a 
Ppump of 29.3 mmHg while lymphedema patients had a significantly lower Ppump of 13.2 
mmHg, indicating reduced lymph transport capabilities in lymphedema patients. More 
recently this technique was also applied to assess the decline in Ppump associated with 
aging(250), although currently the technique does not take into account changes in tissue 
compliance and how this might affect the transmission of the externally applied pressure 
to the lymphatic vessel.  
 NIR lymphatic imaging has the potential to revolutionize the study of lymphatic 
transport phenomena, especially in the context of lymphatic disorders, with the 
development of new imaging techniques and quantification metrics.  However, the 
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technique is still in its infancy and several advancements need to be made to maximize 
the effectiveness of lymphatic transport functional assessment.  This leads to three 
specific aims that will form the basis of this work.  First, we will characterize and 
optimize NIR imaging specifically for imaging the dynamics of dermal collecting vessels.  
Secondly we will characterize the physiology of multiple lymphatic collectors draining a 
single tissue space and explore the effects of various flourophores in time course 
imaging.  Finally, we will create a new model of lymphedema specifically designed to 
use NIR imaging to quantify changes in lymphatic collecting vessel function associated 
with the disease.  Cumulatively, these aims will provide necessary advances in our 
understanding of the physics (aim 1) and the physiology (aim 2) of NIR lymphatic 
imaging, which will enable a novel and impactful assessment of the relationship between 
lymphedema and lymphatic pump function (aim 3). 
Specific Aims 
Specific Aim 1 
 There has been very little experimentation or discussion on the effects of the 
interstitial environment or the various quantifiable parameters historically used with this 
technique, such as the effects of vessel depth and scattering on the ability to resolve 
differences in vessel diameter or the effects of protein binding on ICG fluorescence.  
Quantifying these and other effects will allow for potential optimization of component 
selection and configuration, will establish performance metrics of imaging functionality, 
and will provide more detail in regards to the limitations of the technique as a non-
invasive tool for quantifying lymphatic function. 
 Therefore, we will characterize and optimize NIR imaging for the visualization 
and quantification of lymphatic pump function specifically focusing on 
excitation/emission wavelengths, tissue penetration depths, and hardware optimization. 
Furthermore, we will validate the performance of the NIR imaging system to detect 
functional changes in lymphatic transport by intentionally modulating lymphatic 
contractility in vivo using nitric oxide (NO) and performing in vivo NIR imaging to 
detect the resulting changes in lymphatic function. 
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Aim 1 Hypotheses 
H1.1: ICG fluorescence in lymphatic collectors is dependent upon protein concentration 
and optimizing the ICG solution will lead to an increased SNR in the vessels. 
H1.2: Dermal application of nitric oxide ointment will reduce lymphatic function in a 
manner that can be quantified with NIR lymphatic imaging. Specifically, dermal nitric 
oxide ointment will: 
 H1.2.1: increase transport time  
 H1.2.2: decrease packet frequency 
 H1.2.3: decrease packet velocity. 
Specific Aim 2 
 The field is still learning to understand and interpret the wealth of data NIR 
functional lymphatic imaging can uniquely provide compared to other modalities.  In 
particular, recent work has suggested that functional differences exist between various 
collecting vessels in a rodent hind limb (171), but no studies have specifically examined 
the differential transport abilities of multiple collecting vessels draining a single tissue 
space.  Such an analysis is a necessary advancement of NIR functional lymphatic 
imaging, which has historically focused on quantification of only a single vessel, to better 
understand the physiology of draining lymphatic networks at the tissue level. 
 Therefore, we will simultaneously characterize the functional transport 
capabilities of the two collecting vessels in the rat tail model using NIR lymphatic 
imaging.  The rat tail provides the simplest model of lymphatic network drainage for NIR 
imaging purposes due to the simple geometry and the consistent position of the two 
collecting vessels.  Using the rodent tail also allows comparisons to many previous 
studies as it has been one of the most widely used models in lymphatic research, 
providing insight into basic lymphatic physiology and lymph flow (111, 268), 
lymphangiogenesis (30, 42, 78, 276), and lymphedema pathology (195, 237, 279). The 
results of this characterization will establish a framework by which future lymphatic 
research can be performed using NIR imaging in the tail model and will enhance our 
understanding of differential vessel function. 
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 Additional controversy also remains regarding the most appropriate fluorophore 
for NIR lymphatic imaging.  Several studies are beginning to explore novel probes with 
higher quantum yields specifically for NIR lymphatic imaging(47, 96, 124, 172), but the 
most commonly used probe to date has been indocyanine green (ICG).  Despite the low 
quantum yield of the molecule, ICG remains the hallmark of NIR lymphatic imaging 
because it is FDA approved for use in humans and represents the most likely probe for 
the development of a point-of-care diagnostic.  However, the literature is mixed regarding 
the effects of ICG on lymphatic function.   
 It has been shown in isolated lymphatic vessels that ICG inhibits vessel 
contraction in a dose-dependent manner and continues to alter function even beyond 
complete washout from the vessel (73).  Given that near-infrared fluorophores have been 
shown to accumulate in the intracellular space (69), and ICG, in particular, has been 
shown to exhibit extremely cumulative cellular uptake (1, 62), we hypothesize that ICG 
is retained in the tissue space and contributes to a decrease in lymphatic function for an 
extended period of time following initial injection.  A follow-up study using NIR imaging 
was unable to detect changes in lymphatic function after ICG injections of various 
concentrations (5), but the study only examined this phenomenon at one time point. 
 Therefore, we will first examine the retention of ICG in the tissue space of the rat 
tail and measure lymphatic function with NIR imaging beyond the duration of retention 
to analyze the time course changes in lymphatic function following initial ICG injection.  
For comparison purposes, we will also perform this analysis with a competing NIR 
fluorophore, the LI-COR IRDye 800CW PEG.  The results will contribute to a further 
characterization of the rat tail model for NIR lymphatic imaging and will inform future 
studies involving multiple, repeat injections of NIR probes in this model. 
Aim 2 Hyopotheses 
H2.1:  When multiple collecting vessels drain the same tissue space, they will have 
heterogeneous transport capacities, and may exhibit a differential response to stimuli. 
H2.2:  Lymphatic transport as measured through NIR imaging will vary as a function of 
time after initial injection due to the transient alteration in interstitial fluid pressure 
resulting from the bolus injection. 
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H2.3: ICG has a time-delayed effect on lymphatic function such that it will decrease 
lymphatic transport capacity in the context of time-course experiments with repeat 
fluorophore injections.  Specifically: 
H2.3.1: ICG remains present in the tissue space for an extended period of time 
following a bolus injection for NIR lymphatic imaging. 
H2.3.2: ICG will cause a reduction in lymphatic function in a time-delayed 
manner such that repeat measurements at later time-points will exhibit significant 
reductions in NIR lymphatic measurements.  This time-course of reduced 
lymphatic function may correlate with the retention of ICG in the tissue space. 
H2.3.3: ICG will demonstrate evidence of inflammation that will correlate with 
retention of the dye in the tissue space.  
Specific Aim 3 
 It remains unclear how the response of the lymphatic system during the post-
trauma period correlates with the onset and progression of lymphedema, which has 
severely limited our ability to understand the disease mechanism and cascade.  Since 
lymphatic flow is driven primarily through the contractility of collecting lymphatic 
vessels, the ability to quantify lymphatic pump function through the imaging of 
functional lymphatic transport in the context of early lymphedema onset would greatly 
enhance our understanding of the disease progression.  We hypothesize that lymphedema 
is associated with a progressive loss of lymphatic function, which can be visualized and 
subsequently quantified with NIR imaging, thus affording novel insights into the disease 
cascade.  The latency period commonly associated with lymphedema, in particular, 
motivates a hypothesis of remodeling-induced lymphatic failure, which has begun to 
gather support in the literature(136).  Importantly, however, all of the animal models 
reported in the literature to date have severed all of the collecting vessels draining the 
tissue space of interest, and the analysis has focused exclusively on morphological 
changes occurring in the dermal layer and functional changes occurring in the initial 
lymphatics.  No study to date has investigated the changes in collecting vessel function 
associated with lymphedema, and no model currently exists that allows preservation of 
collecting vessel trunks. 
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 Therefore, we will develop a new rodent tail model of lymphedema allowing for 
selective preservation of certain lymphatic collectors in order to track changes in the 
collecting vessel transport metrics over time using NIR lymphatic imaging.  We will take 
baseline NIR functional measurements before surgery, immediately after surgery, and in 
regular follow-up intervals to record changes in collecting vessel transport function over 
the course of the disease cascade.  The goal is to develop a model that exhibits similar 
pathological progression as the classic rodent tail model of lymphedema while preserving 
a single intact collecting vessel trunk.  Doing so will provide the first opportunity to study 
the link between lymphedema progression and lymphatic transport as well as help to 
generate new insights into the potential mechanisms of lymphatic failure during disease 
progression. 
Aim 3 Hypotheses 
H3.1: Ligating the mouse tail such that one lymphatic collector remains intact will create 
a pathological model of lymphedema while simultaneously allowing NIR functional 
metrics to be obtained from the intact vessel.  The tails may exhibit slightly less swelling 
than the standard full ligation tail model. 
H3.2: Ligating the dominant vessel will produce significantly increased swelling as 
compared to ligation of the dominant vessel. 
H3.3: Swelling will correlate with reductions in lymphatic function as quantified through 
NIR lymphatic imaging. 
H3.4: The disease cascade will contribute to remodeling of the intact collecting vessel 
such that the pumping capacity is reduced.  
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CHAPTER 2: SENSITIVITY ANALYSIS OF NEAR-INFRARED 
FUNCTIONAL LYMPHATIC IMAGING 
  
Near-infrared (NIR) imaging of lymphatic drainage of injected indocyanine green (ICG) 
has emerged as a new technology for clinical imaging of lymphatic architecture and 
quantification of vessel function, yet the imaging capabilities of this approach have yet to 
be quantitatively characterized.  Therefore, we sought to quantify its capabilities as a 
diagnostic tool for lymphatic disease. Imaging was performed in a tissue phantom for 
sensitivity analysis and in hairless rats for in vivo testing. To demonstrate the efficacy of 
this imaging approach to quantifying immediate functional changes in lymphatics, we 
investigated the effects of a topically applied nitric oxide (NO) donor glyceryl trinitrate 
ointment (GTNO). Premixing ICG with albumin induces greater fluorescence intensity, 
with the ideal concentration being: 150 µg/mL ICG and 60 g/L albumin.  ICG 
fluorescence can be detected at a concentration of 150 µg/mL as deep as 6 mm with our 
system, but spatial resolution deteriorates below 3mm, skewing measurements of vessel 
geometry. NO treatment slows lymphatic transport, which was reflected in increased 
transport time, reduced packet frequency, reduced packet velocity, and reduced effective 
contraction length.  NIR imaging may be an alternative to invasive procedures measuring 
lymphatic function in vivo in real time. 
Introduction 
 The lymphatic system plays a critical role in regulating tissue fluid balance by 
draining the interstitial space and preserving protein concentrations to maintain oncotic 
pressure(57).  If the natural function of the lymphatic system is disrupted, several 
pathologies can develop, most notably lymphedema, which often results in irreversible 
tissue damage presumably through the disruption of lymphatic transport, thus leading to 
subsequent interstitial fluid stagnation and lipid accumulation in the affected tissues(175).  
However, our current understanding of the lymphatic vasculature pales in comparison 
with the blood vasculature, a phenomena that can partly be attributed to the lack of in 
31 
vivo imaging techniques suitable for visualizing lymphatic vessels.  In the case of 
lymphedema, in particular, a major limitation in the development of new treatments has 
been the lack of in vivo imaging diagnostics capable of quantifying differences in the 
dynamic pump function of lymphatic vessels in real-time(181). 
 Recently, the lymphatic system has garnered increased interest as its roles in 
tumor metastasis(97), dermal drug delivery(81), chronic inflammation(93), and lipid 
transport(56) are beginning to be appreciated.  With the new understanding of the role of 
lymphatic vessels in disease processes and therapies there is now a greater need for major 
advances in the diagnostic imaging tools available to adequately visualize and quantify 
lymphatic pump function.  Since lymphatic flow is driven primarily through the 
contractility of collecting lymphatic vessels(148, 266), the ability to quantify lymphatic 
pump function through the imaging of functional lymphatic contractions and fluid flow 
would greatly improve the understanding of lymphatic contractile physiology and 
enhance the diagnosis of disease states.  However, the two traditional gold standards of 
clinical lymphatic imaging, lymphoscintigraphy and magnetic resonance imaging (MRI), 
while very effective for systemic lymphatic mapping, are inadequate for the assessment 
of lymphatic function because draining vessels are below the spatial resolution of MRI 
and lymphoscintigraphy lacks the real-time temporal resolution needed to image the 
dynamics of lymphatic contractile function(21, 141, 173, 212). 
 Near-infrared (NIR) imaging technologies may provide the ideal solution to 
functional lymphatic imaging as both a research tool and a disease diagnostic because 
NIR light resides in the optimal wavelength range where light absorption and scattering 
are low in biological tissue and there is minimal autofluorescence, thus affording deeper 
penetration depths and excellent contrast and spatial resolution, all of which are vital for 
measuring lymphatic contractile properties(177). NIR imaging with an FDA-approved 
fluorescent dye, indocyanine green (ICG), has recently emerged as a novel method for 
quantitative assessment of lymphatic function in animals and humans (107, 108, 178, 
180, 249); a technique in which ICG is injected intradermally, excited with a laser diode, 
and imaged with an NIR-sensitive detector as it is taken up by the lymphatic system(211, 
247). 
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 NIR lymphatic imaging, although in its infancy, has shown great promise to 
enhance the understanding of functional lymphatic transport characteristics both in health 
and disease as the technology has the potential to develop into an early-stage diagnostic 
of lymphatic dysfunction(2, 209, 247, 248).  Such a device would be strongly suited to 
enhance the diagnosis and treatment of lymphatic disorders through the visualization and 
quantification of changes in functional lymphatic transport before clinical manifestations 
are present and tissue damage is irreversible. Current NIR lymphatic imaging technology 
has been quite successful at demonstrating differences in lymphatic function and 
architecture in patients who have already been diagnosed with lymphedema(128, 180, 
247), differences in lymphatic function in response to manual lymphatic drainage(241) 
and pneumatic pressure devices(2), as well as a decline in lymphatic pumping pressure in 
response to aging(250).  However, it is currently unclear how effective this approach will 
be at predicting lymphedema disease risk or providing early detection, as most of its 
successes to date have involved showing differences in lymphatic function after 
significant deterioration has already occurred. Additionally, there has been very little 
experimentation or discussion on the effects of the interstitial environment on the various 
quantifiable parameters historically used with this technique, such as the effects of vessel 
depth and scattering on the ability to resolve differences in vessel diameter or the effects 
of protein binding ICG fluorescence.  Quantifying these and other effects will allow for 
potential optimization of component selection and configuration, will establish 
performance metrics of imaging functionality, and will provide more detail in regards to 
the limitations of the technique as a non-invasive tool for quantifying lymphatic function.   
 The purpose of this study, therefore, is to investigate these issues for 
characterizing and optimizing NIR imaging for the visualization and quantification of 
lymphatic pump function. Furthermore, the current state of the art for studying lymphatic 
contractile dynamics and their biophysical and molecular regulation in vivo requires 
invasive, terminal procedures(32, 53, 55, 114), but NIR lymphatic imaging may have the 
potential to generate similar data regarding lymphatic function in a completely 
noninvasive manner.  Therefore, we will validate the performance of the NIR imaging 
system to detect functional changes in lymphatic transport by intentionally modulating 
lymphatic contractility in vivo using nitric oxide (NO) and performing in vivo NIR 
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imaging to detect the resulting changes in lymphatic function.  We expect NIR imaging 
to be able to detect functional changes in lymphatic transport after differential 
applications of NO, which may establish a novel research tool for studying the regulatory 
effects of NO on lymphatic pump function in vivo in real time. 
Hypotheses 
H1.1: ICG fluorescence in lymphatic collectors is dependent upon protein concentration 
and optimizing the ICG solution will lead to an increased SNR in the vessels. 
H1.2: Dermal application of nitric oxide ointment will reduce lymphatic function in a 
manner that can be quantified with NIR lymphatic imaging. Specifically, dermal nitric 
oxide ointment will: 
 H1.2.1: increase transport time  
 H1.2.2: decrease packet frequency 
 H1.2.3: decrease packet velocity. 
Materials and Methods 
Near-Infrared Functional Lymphatic Imaging System Set-Up 
 The NIR lymphatic imaging device, which is depicted in Figure 4, was developed 
using a 150mW 808nm laser diode (Thorlabs part no. M9-808-0150) powered by 
accompanying diode driver and temperature control boxes to provide excitation light.  A 
20° beam diffuser (Thorlabs part no. ED1-C20) was mounted in front of the diode to 
achieve a uniform excitation field of approximately 75cm2 with less than 1.9 mW/cm2.  
Fluorescence emission centered at 840 nm was captured using a PIXIS 1024B back-
illuminated CCD camera (Princeton Instruments) with an attached Infinity K2/SC video 
microscope lens (Edmund Optics) and a bandpass filter (CW:840 nm, FWHM:15 nm, 
Omega Optical).  NIR images were recorded via a custom LabView (National 
Instruments) image acquisition code. 
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Figure 4: NIR lymphatic imaging system schematic. Excitation light is provided by 150mW 808nm 
laser diode powered by accompanying diode driver and temperature control boxes.  Emission light 
centered at 840nm is captured by a CCD Camera with an Infinity K2/SC video microscope lens and a 
bandpass filter (CW:840 nm, FWHM:15 nm). 
ICG Solution Preparation  
 To determine the optimal excitation and emission wavelength of ICG for use in 
NIR lymphatic imaging we created an albumin-physiological salt solution (APSS) (in 
mM: 145.00 NaCl, 4.7 KCl, 2.0 CaCl2, 1.17MgSO4, 1.2NaH2PO4, 5.0 dextrose, 2.0 
sodium pyruvate, 0.02 EDTA, 3.0 MOPS, and 10g/L bovine serum albumin)(72) 
designed to mimic interstitial fluid and added a commonly used concentration of 250 
µg/mL of ICG (Across Organics)(209) to simulate an injection of ICG into the interstitial 
space.  For comparison purposes, the same concentration of ICG was also dissolved in 
0.9% saline water.  Peak excitation of both solutions was recorded using a 
150mW 
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spectrophotometer (Hitachi U-2900) and peak emission at the previously recorded peak 
excitation was recorded using a fluorometer (Shimazu RF-1501).  
 The optimal ICG solution for maximizing fluorescence yield within the dermal 
layer was determined by dissolving various concentrations of ICG ranging from 0.01 
µg/mL to 1000 µg/mL in 0.9% saline and in APSS solutions with albumin concentrations 
ranging from 0 g/L to 100 g/L. The various solutions were flowed through the tissue 
phantom at a depth of 2mm to simulate flow through a dermal lymphatic vessel.  The 
vessel was imaged using the NIR system, and fluorescence intensity was recorded for 
each sample to determine the optimal ICG and albumin concentrations.  In order to 
quantify the enhancement of premixing ICG with albumin, follow-up testing was 
performed to compare the signal to noise ratio (SNR) of the optimal ICG/albumin 
solution (150 µg/mL ICG + 60 g/L albumin) and ICG alone (150 µg/mL ICG) both at the 
injection site and 10 cm downstream in the collecting vessel, where SNR was calculated 
as .  Functional lymphatic testing (detailed below) was 
also performed to verify that premixing ICG with albumin does not alter lymphatic 
function, as measured by transport time, packet frequency, and packet velocity. 
Tissue Phantom Preparation  
 In order to characterize the parameters of NIR lymphatic imaging in the dermis, a 
tissue phantom was created with the same optical properties as the dermal layer.  Mock 
lymphatic vessels of known diameters were created in the tissue phantom at known 
depths, thus affording complete control over the phantom and allowing idealized 
characterization of NIR imaging capabilities regarding spatial resolution and signal 
penetration depth.  As can be seen in Figure 5, the tissue phantom was molded in a 
standard petri dish using a mixture of 97.52% silicone elastomer base (Sylgard 184, Dow 
Corning), 2.22% Aluminum Oxide (Sigma Aldrich), and 0.26% cosmetic powder (Max 
Factor Crème Puff Deep Beige 42) according to previously published methods(123).  
Channels were created in the tissue phantom molds by suspending standard copper 
electrical wire of known diameters at known depths in the mold prior to curing and 
removing the wires after curing.  The tissue phantom was also connected to a syringe 
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pump (PHD 2000, Harvard Apparatus) to flow various ICG solutions through the mock 
vessels for imaging, a schematic of which is depicted in Figure 5-D. 
 
Figure 5: Tissue phantom schematic and operation. (A) Tissue phantoms were molded in standard 
petri dishes using a mixture of 97.52% silicone elastomer base, 2.22% Aluminum Oxide, and 0.26% 
cosmetic powder.  Channels were created in the tissue phantom molds by suspending standard 
electrical wire of known dimensions at known depths. (B) Image of the resulting channels after the 
molds are cured and the wires are removed.  This is an example image created using 100% silicone to 
allow visualization of the channels.  (C) Image of the final tissue phantom construct in which the 
channel outlets can be seen protruding from the side of the phantom.  (D) The tissue phantom was 
connected to tubing containing preloaded “packets” of ICG to test the spatial and temporal 
resolution of the NIR imaging system.  The flow rate through the tissue phantom was precisely 
controlled with a syringe pump and the ICG packets were imaged as they passed through the 
phantom. 
Sensitivity Analysis of NIR System  
 Mock vessels of 1mm diameter were created in a phantom at depths ranging from 
1mm to 10mm in 1mm increments, the optimal ICG solution (150 µg/mL ICG, 60 g/L 
albumin) was loaded into each of the mock vessels, and fluorescence intensity was 
recorded at each depth in order to characterize the change in signal sensitivity of the NIR 
system as a function of depth.  Vessel diameter calculations were performed at all depths 




to characterize the scattering effect on apparent vessel diameter.  Fluorescence intensity 
measurements were recorded for 4 conditions to quantify excitation light leakage: (1) 
CCD shutter closed (background), (2) excitation light source on without ICG in the 
phantom, (3) low concentration of ICG (1 µg/mL + 60 g/L albumin), and (4) ideal 
concentration of ICG (150 µg/mL + 60 g/L albumin). 
 ICG typically flows through lymphatic vessels in the form of discrete 
“packets”(107, 211), presumably due to valve closure that is known to occur during 
periods of short flow reversal, when a favorable pressure gradient exists to close the 
valve(50, 54). To mimic the pulsatile packet flow of ICG in lymphatic vessels, mock ICG 
packets were created by preloading a length of tubing with drops of ICG solution 
separated by olive oil (to prevent mixing of the ICG packets through diffusion).  A 
syringe pump was then used to flow the packets of ICG through the tissue phantom at 
known velocities to test the accuracy of a custom lymph velocity quantification algorithm 
we developed.  The algorithm, a similar version of which was first reported by Sharma et 
al. in 2007(211), utilizes line intensity profiles placed sequentially along a lymphatic 
vessel in the direction of flow at known distances from each other (Figure 6-A).  The line 
intensity profiles record spikes when packets pass over that particular area (Figure 6-B), 
and by measuring the time between spikes in the three sequential line profiles, average 
velocity of packets can be calculated.  
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Figure 6: Quantification of ICG packet travel through tissue phantom. “Packets” of ICG were 
created by separating small amounts of ICG with olive oil (to prevent mixing of separate packets) in 
a segment of tubing connected to the tissue phantom.  A syringe pump was used to precisely control 
the flow rate of the fluid through the tubing/tissue phantom construct. A custom code was used to 
process the data by calculating intensity values over three line profiles placed sequentially along the 
channel.  (A) Example image of ICG packets flowing through the tissue phantom at a depth of 1 mm. 
The three lines depicted show the placement of the three line integrals used in the processing 
algorithm to detect fluorescence intensity. (B) Example of the fluorescence intensity plots at the three 
line intensity profiles over time.  Peaks in fluorescence intensity correspond to packets traveling over 
the lines.  Fluid velocity can be calculated using the known dimensions of the channel and the time 
intervals between packets reaching sequential line profiles. 
In Vivo Imaging  
 Lymphatic function was quantified in vivo in the tail of six-week-old female 
hairless rats (Charles River Laboratories, Wilmington, MA) that were divided into a 































application of a glyceryl trinitrate ointment (GTNO) (0.2% wt/wt, Rectogesic, Care 
Pharmaceuticals, commercially available), which is an ointment with an NO donor group 
that has previously been reported to slow lymphatic transport time(198).  The control 
group did not receive any topical treatment.  Both groups were anesthetized with an 
intramuscular injection of Fentanyl (0.12 mg/kg), Droperidol (6 mg/kg), and Diazepam 
(2.5 mg/kg given 10 minutes after Fentanyl/Droperidol). The treatment and control 
groups were then both given 10 µL intradermal injections of ICG (150 µg/mL ICG, 60 
g/L albumin) in the tip of the tail (given 1 minute after the GTNO application for the 
treatment group).  
 The NIR lymphatic imaging system was positioned such that the excitation source 
and the field of view of the CCD emission detector were centered on the rats’ tail 10cm 
downstream (towards the base of the tail) from the injection site at the tip of tail. The 
animals were imaged continuously from the time of injection until 20 minutes post-
injection with a camera exposure time of 0.05 seconds. To evaluate lymphatic function in 
each of the rat subjects, three parameters were measured: the time necessary for the bolus 
injection of ICG to travel the 10 cm distance from injection site to emission recording site 
(transport time), the average velocity of the packets traveling through the field of view of 
the recording site, and the average frequency of packets passing through the field of view.   
The transport time was calculated as the time between ICG injection and the arrival of 
fluorescence in the field of view 10 cm downstream from the injection site.  The arrival 
of fluorescence was defined as a 20% increase in fluorescence intensity in the collecting 
vessel. A plot of fluorescence intensity over time during fluorescence arrival can be seen 
in Figure 7. 
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Figure 7: Fluorescence intensity over time during fluorescence arrival. (A) Image showing location of 
line profile for fluorescence arrival example. (B) Example plot of intensity versus time during arrival 
of fluorescence. 
 Packet frequency and velocity were measured using plots of fluorescence 
intensity over time generated from two regions of interest (ROIs) in a collecting vessel.  
ROIs were placed approximately 3-6 mm apart in regions of the vessel exhibiting large 
fluctuations in fluorescence intensity over time, where packet movement could easily be 
visualized and quantified.  Packet frequency and velocity measurements began 10 frames 
after the arrival of fluorescence (to allow fluorescence values to stabilize) and measured 
for a duration of 10 packets.  Of the two vessels in the tail, measurements were taken 
only on the vessel first producing fluorescence.  Average packet frequency was 
calculated as 10 packets divided by the time necessary for 10 packets to occur (in 
minutes).  Average packet velocity was calculated as the distance between the two ROIs 
divided by the average time necessary for packets to travel between the two ROIs (as 
























examples of ROI selection and intensity versus time plots of the 10 packets used for 
frequency and velocity measurement.   
 
Figure 8: Example intensity plots over time for normal and GTNO treatment conditions. (A) Image 
showing location of line profiles for normal condition example. (B) Image showing location of line 
profiles for GTNO treatment condition example. (C) Example plot of intensity versus time for 
normal condition.  (D) Example plot of intensity versus time for GTNO treatment condition. 
 To calculate the average delay time between contractions we wrote a Matlab 
script that analyzes a given video sequence to find the region of highest fluctuation within 
the vessel. The fluorescence in this region was then quantified as a function of time and 
that signal was processed by the code to calculate the average number of frames for each 
interval in which there was no fluorescence fluctuation. This value was multiplied by the 
time interval between frames and reported as the average delay time, td, for that vessel. 
 The data for each of the three functional imaging parameters was averaged for the 
treatment and control group, subsequently checked for normality using the Anderson-
Darling test, and analyzed for statistical significance using a 2-sample t-test. 
Quantifying Lymphatic Function Parameters 
 We sought to define a term describing the average length a packet of fluid would 
travel between contraction events (referred to as the effective contraction length, 
€ 
L*) as a 






















































system. Briefly, the time, t, it would take for the bolus injection to travel 10 cm along the 









f  is the average 
frequency of contraction events. Knowing the rate of contraction events and the average 
time it takes for the moving front to reach a fixed distance allows us to estimate the 
average length each contraction event transports the fluid.  
 Each contraction event is composed of a delay time and a contraction time in 




= tL* + td
. From this equation we can estimate  
€ 
tL*  given that we calculate the other two parameters 
from the image analysis. We also sought to develop a method for describing the systolic 
pumping power of the vessel from parameters measured by our system. During a 
contraction event the fluid packet accelerates to a maximum velocity and then decelerates 
back to rest, having traveled a distance L* over the entire cycle. If we assume that these 
two events are split evenly over this cycle, then the distance traveled by the packet during 
the systolic phase is L*/2. To estimate the acceleration of the fluid packet during the 
systolic phase we divide the average maximum packet velocity (which is measured as 
described above), Vp, by the duration of systole, which we estimate as 
€ 
tL* /2. From these 






























 as the average systolic pumping power per unit mass. 
Characterization of Packets in Isolated Vessels and In-Vivo 
 Two experimental setups were used to help characterize packets, as they appear in 
collecting vessels in-vivo.  In the first setup, mesenteric collecting vessels were excised 
from Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) and were 
cannulated and pressurized in a living system chamber according to previously published 
methods(72).  A solution containing the commercially available fluorophore LI-COR 
IRDYE 800CW PEG (LI-COR Biosciences, Nebraska, USA) diluted to 10% of the 
43 
manufacturer’s recommended concentration for lymphatic imaging was flowed through 
the vessel.  Images were taken in brightfield to record vessel contraction and in NIR to 
observe transport of the dye through the vessels.  The purpose was to assess the 
relationship between the appearance of packets and contractions of the vessel. 
 The second experimental setup to characterize packets utilized in-vivo NIR 
imaging with the skin removed.  In-vivo NIR imaging was performed as detailed above 
with the exception that the imaging was performed in the forelimb and the injection was 
given in the footpad.  Once fluorescence arrived in the collecting vessels downstream 
from the injection site, images were taken with the skin on and with the skin off to 
determine the effect of skin on the appearance of packets. 
Results 
ICG Spectrum and Fluorescence 
 The excitation peaks for ICG dissolved in saline and APSS were approximately 
785 nm and 805 nm respectively while the emission peaks of ICG in saline and APSS 
were approximately 815nm and 840nm respectively (Figure 9). 
 
Figure 9: ICG dissolved in albumin salt solution (APSS) exhibits a shift in the excitation/emission 
spectrum. Excitation and emission curves were generated for ICG (250 µg/mL) dissolved in 0.9% 
saline (dotted lines) and APSS (solid lines).  A shift of approximately 20 nm was observed in the 



























nm and 785 nm respectively.  A shift of approximately 25 nm was observed in the emission spectrum 
of ICG dissolved in APSS versus saline, with peak fluorescence occurring at 840 nm and 815 nm 
respectively. These spectra guided the design of excitation and emission detection wavelengths of the 
NIR imaging system. 
 ICG fluorescence was highly dependant on albumin concentration and the 
intensity reached a maximum at an albumin concentration of 60 g/L (902.8 µM) (Figure 
10-A), and the maximum fluorescence yield at this albumin concentration was produced 
at an ICG concentration of 150 µg/mL (193.5µM) (Figure 10-B). Thus the solution 
producing maximal fluorescence was 150 µg/mL ICG and 60 g/L albumin. When 
injected into a rat tail, premixing 150 µg/mL ICG with 60 g/L albumin produced a greater 
SNR as compared to 150 µg/mL ICG alone with more than a four-fold increase in SNR 
observed in the collecting vessels  (Figure 10-C) (p<0.05).  Additional functional 
lymphatic testing was performed in response to ICG and ICG/albumin injections, and no 
significant differences were observed in transport time, packet frequency, or packet 
velocity (Figure 11). 
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Figure 10: Pre-binding ICG with albumin enhances fluorescence and the resulting SNR upon in vivo 
intradermal injection. Fluorescence intensity through the phantom at a depth of 2 mm was measured 
for various concentrations of ICG and albumin to optimize the two concentrations to produce 
maximum fluorescence intensity of the ICG solution. (A) Peak ICG fluorescence intensity was 
measured as a function of albumin concentration in APSS ranging from 0 g/L albumin to 100 g/L 
albumin.  Peak ICG fluorescence was produced at 60 g/L albumin. (B) Fluorescence intensity of ICG 
dissolved in 60 g/L was measured as a function of ICG concentration to determine the final 
concentrations of the optimal ICG solution for producing maximum fluorescence intensity.  





































































µg/mL ICG solution and 150 µg/mL ICG premixed with 60g/L albumin were injected into rat tails 
and the signal to noise ratio (SNR) was calculated for each sample at the injection site and 10 cm 
downstream in the collecting lymphatic vessel.  ICG premixed with albumin produced greater than a 
four-fold increase in SNR compared to ICG alone from 1.8dB to 7.8dB in the collecting vessels and 
an increase from 10.9dB to 14.2dB at the injection site. Error bars represent standard deviation. 
*=p<0.05. 
 
Figure 11: Pre-mixing ICG with albumin does not alter lymphatic function compared to ICG alone. 
Results of functional lymphatic testing reveal no significant differences between injection of ICG 
alone and ICG + albumin in the tails of rats (n=3). (A) No significant difference in transport time to 
travel 10 cm. (B) No significant difference in packet frequency.  (C) No significant difference in 
packet velocity. 



















































 The minimum detectable concentration of ICG at 2mm depth was 0.1 µg/mL, and 
ICG emission was detectable as deep as 6 mm with the signal at depths below 7 mm 
being indistinguishable from background (Figure 12).  Quantifying excitation light 
leakage showed a 4-fold increase of signal over the thermal noise background. However, 
even low ICG concentrations produced a signal much larger than that due to leakage and 
values of fluorescence typically seen in the vessel in vivo have fluorescence intensity 
values 14 fold greater than the excitation light source (Figure 13).  Vessel diameter 
calculations were very accurate at a depth of 1mm with a 0.74% error, but error increased 
with depth to 1095.06% error at 5mm and was incalculable beyond 5mm due to excessive 
scattering. The results also show that the calculated velocities were within 1% of the true 
velocities over a range from 0.15 – 1.5mm/s (Figure 14). 
 
Figure 12: ICG can be detected up to a depth of 6 mm with minimal loss of spatial resolution at a 
depth of up to 3 mm. The optimal concentration of ICG solution (150 µg/mL ICG, 60 g/L albumin) 
was flowed through the tissue phantom at depths between 1 mm and 10 mm in 1 mm increments to 































































the tissue phantom from 1 mm to 6 mm, which was the depth limit of detection.  (B) Plot of minimum 
detectable ICG concentration at 2 mm depth in the tissue phantom.  Minimum detectable ICG 
concentration was 0.1 µg/mL.  (C) Plot of ICG fluorescence intensity as a function of depth showing 
fluorescence intensity decreased successively with depth until 7 mm, which was indistinguishable 
from background.  The depth limit of signal detection was 6 mm.  (D) The apparent diameter of the 
channels at each depth was measured and compared to the true diameter of the channel to determine 
the accuracy of vessel diameter detection as a function of depth.  At 1 mm there was a 0.74% error 
between the true diameter and the measured diameter.  Percent error increased with depth to a 
maximum of 1095.06% error at 5 mm. 
 
Figure 13: Characterization of excitation light leakage.  Intensity values were quantified for 4 
conditions: (1) CCD shutter closed (background), (2) excitation light source on and phantom present 
without ICG, (3) low concentration of ICG in tissue phantom (1 µg/mL + 60 g/L albumin), and (4) 
ideal concentration of ICG (150 µg/mL + 60 g/L albumin).  The results show that the excitation light 
produces a 4 fold increase in intensity over background, but the ideal concentration of ICG produces 































Figure 14: Calculated packet velocity predicts true velocity with less than 1% error.  Packets were 
flowed through the tissue phantom at a depth of 3 mm at velocities ranging from 0.15 – 1.5  mm/s.  
Velocities were calculated using a custom algorithm and compared to the known true velocities.  
Calculated velocities were accurate to within less than 1% error. 
Quantifying Functional Effects of NO on Lymphatics In Vivo 
 Application of GTNO significantly reduced lymphatic function (Figure 15). 
Transport time increased from 60 seconds under normal conditions to 414 seconds after 
GTNO application (p<0.01).  Packet frequency decreased from 5.92 packets per minute 
and under normal conditions to 3.1 packets per minute after GTNO application (p<0.05). 
Packet velocity decreased from 1.50 mm/sec under normal conditions to 0.48 mm/sec 
after GTNO application (p<0.05). GTNO application decreased effective contraction 
length from 17.6 mm to 5.1 mm (p<0.0005). Contraction duration after GTNO 
application was significantly increased from 4.1 sec to 5.4 sec (p<0.05) and systolic 
pumping power per unit mass was drastically reduced after GTNO application from 1.25 



























Figure 15: Dermal nitric oxide delivery significantly reduces lymphatic pump function. 10µL of ICG 
(150µg/mL ICG, 60g/L albumin) was injected intradermally into the tip of the tail hairless rats 
divided into a treatment group that received a topical application of glyceryl trinitrate ointment 
(GTNO) prior to ICG injection (n=4) and a control group that did not receive any treatment prior to 
ICG injection (n=4).  The NIR lymphatic imaging system was positioned to view the tail 10 cm 
downstream (towards the base of the tail) from the injection site. (A) The time required for the initial 
bolus injection of ICG to travel 10 cm downstream (transport time) significantly increased after 
GTNO application. (B) Packet frequency was significantly reduced after GTNO application. (C) 
Packet velocity was significantly reduced after GTNO application. (D) Effective contraction length 
was significantly decreased after GTNO application.  (E) Contraction duration was significantly 
increased after GTNO application. (F) Contraction power per unit mass was decreased after GTNO 
treatment. *=p<0.005. 






















































































































 The isolated vessel setup revealed that vessel contraction caused the appearance 
of packets in NIR imaging (Figure 16).  As the vessel constricts below a certain 
threshold, the amount of fluorophore in the local region is too low to be detected with 
NIR imaging.  Comparing vessel contraction dynamics under brightfield to the 
appearance of packets in NIR imaging reveals that the two phenomena are perfectly in 
sync.  Furthermore, the in-vivo skin flap experiment revealed that areas of NIR dye 
stagnation occur immediately downstream (proximal) from the valve regions in the sinus 
of the lymphangions (Figure 17).  The sinuses are almost always visible under NIR, but 
the remaining segments of the vessel are only visible when it is dilated above a certain 
threshold. 
 
Figure 16: Example plot and representative images of NIR and brightfield imaging of an isolated 
vessel.  Contraction dynamics are in sync with fluorescence intensity indicating that packets are 
created by the contraction and dilation of the vessels. 





































Figure 17: Example NIR image with the skin off and the skin on.  The image on the left shows NIR 
dye flowing through the collecting vessel of a rat forelimb with the skin removed.  Dye can be seen 
pooling in the sinus regions of the vessel, but the entire length of vessel is fluorescent.  The image on 
the right shows the same vessel with the skin on.  The fluorescent signal is much weaker and more 
scattered, and fluorescence is only directly visible in the areas corresponding to the sinus regions, 
where more fluorophore accumulates.  White arrows indicate the three sinus regions in each image. 
Discussion and Conclusions 
Effects of Protein Binding on ICG Fluorescence 
 The NIR lymphatic imaging system that we developed in this study represents a 
departure from the setup of many of the NIR lymphatic imaging systems previously 
reported in that we pre-mixed ICG with albumin, and our system used an excitation 
wavelength of 808 nm and emission wavelength centered at 840 nm(180, 248).  Previous 
systems have used excitation sources of 785 nm, presumably because of the large 
availability of diodes at this wavelength. Our results indicate that ICG produces more 
than a three-fold increase in fluorescence when it binds to albumin, and the peak 
excitation and emission wavelengths are 805 nm and 840 nm respectively.  The same 
effect is observed when ICG is introduced in APSS, thus suggesting that ICG binds to 
albumin in the interstitial space.  Therefore, ICG-based NIR lymphatic imaging systems 
that excite at 808nm and capture emission centered at 840 nm will achieve higher SNR. 
 ICG has previously been shown to rapidly and completely bind to albumin in 
plasma(39). Given that albumin concentration in the interstitium is approximately half of 
Skin Off Skin On 
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its concentration in plasma(67), and the albumin concentration in lymph has been 
measured to be about 40% of its value in plasma(140), it is reasonable to assume that all 
of the ICG present in lymph is bound to albumin as well. This assumption is further 
justified by the fact that the molecular weight of ICG (775 daltons) does not preclude it to 
lymphatic partitioning. Thus, the preferential uptake of ICG into lymphatics that is 
observed following dermal injections suggests that it must be bound to something of a 
much larger size. Since albumin is the most prevalent soluble protein in the interstitium, 
is preferentially taken up into lymphatics after a dermal injection, and binds readily to 
ICG, it follows that even after dermal injection of ICG alone, the dye in the lymph is 
bound to albumin. Pre-mixing ICG with albumin prior to injection thus not only increases 
the fluorescence of the dye, but it also eliminates interstitial albumin availability as a 
limiting factor in ICG uptake into lymphatics.  
 This approach to ICG delivery could be of particular importance when using this 
imaging technique in pathologies such as lymphedema, as the disease often results in 
accumulation of macromolecular proteins in the interstitium(187) that could significantly 
influence the uptake of injected ICG, confounding the interpretation of the experimental 
data. It is important to note that the injection of 10 µl of 60 mg/ml albumin solution, 
while a very small volume, will disrupt the local gradients governing plasma filtration, 
temporarily increasing fluid extravasation from the blood and thus lymph formation. 
However, these values are well within the range of what the lymphatics would be 
expected to resolve during a mild inflammatory event as average flow rates in a 
collecting lymphatic of fasted rats have been reported to range from 40 nl/min to 200 
µl/min depending on the vessel size and state of hydration(54, 246).   
 It should be noted that Ashitate et al. recently reported that ICG alone was a better 
fluorophore for lymphatic visualization in the thoracic duct than ICG pre-bound to 
albumin(12), but there are several differences in experimental setup and technique worth 
exploring.  Firstly, the NIR imaging system they employ excites at 760 nm while our 
system is optimized to excite ICG bound to albumin, which is maximally excited at 805 
nm.  Their experimental setup also does not require imaging through the dermis, and 
thus, does not have to account for scattering and absorption effects since most scattering 
and absorption occurs in the dermis.  Interestingly, Ashitate and colleagues report a SNR 
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for ICG of about 2, which is very similar to our results for ICG in collecting vessels.  
Given that we also report a SNR of nearly 8 for ICG bound to albumin in collecting 
vessels, we are confident pre-binding ICG to albumin provides a more fluorescent tracer. 
Translating this technique into the clinic will produce additional regulatory challenges, 
but premixing the dye with autologous serum prior to dermal injection could provide one 
route of protein-bound ICG delivery. 
Tissue Phantom Sensitivity Analysis 
 The tissue phantom was constructed to recapitulate characteristics of lymphatic 
vessels in vivo that are essential to parameters historically quantified in NIR imaging, 
such as vessel morphology and propulsion frequency and velocity. Specifically, we 
constructed channels of similar size to lymphatics and embeded them in a phantom with 
effective absorption and scattering coefficients of skin at depths characteristic of dermal 
lymphatics in vivo. According to our tissue phantom sensitivity analysis, the NIR 
lymphatic imaging system was capable of detecting ICG fluorescence as deep as 6 mm.  
However, scattering effects resulted in a deterioration of spatial resolution with 
increasing depth, and geometric vessel features became difficult to accurately identify 
below a depth of 3 mm.  These results suggest that the NIR lymphatic imaging system is 
best used to detect vessel geometry and architecture above a 3 mm depth, but an 
assessment of gross ICG accumulation and transport in vivo can be obtained as deep as 
6mm (or perhaps deeper if features being resolved are greater than 1 mm, such as lymph 
nodes).  Given that the average human skin layer is between 1 mm and 3 mm thick(239), 
these imaging characteristics are well-suited for imaging dermal lymphatic function. 
However, clinically lymphatic diseases often result in a severe remodeling of the dermis, 
and fibrosis and lipid deposition can increase the thickness of the dermis well beyond this 
3 mm limit(187).  
 In addition to chronic lymphedema resulting in a thickening of the dermis, it is 
likely that the optical properties of the tissue itself would change as the angiogenesis, 
adipogenesis, and fibrosis often associated with lymphedema would change the 
absorption and scattering coefficients of the dermal layer. Therefore, care should be taken 
in interpreting clinical data from ICG injections in patients with lymphatic disease as the 
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appearance of “hyperplatic” or “dilated” lymphatics could be due in part to changes in the 
thickness and the optical properties of the diseased limb, thus increasing the apparent 
diameter of vessels in these patients. Future studies are warranted to determine how 
exactly these changes would effect the ability of NIR imaging to assess lymphatic 
function in diseased patients. 
 The primary tool in functional ICG imaging is the ability to quantify the kinetics 
of packet flow in lymphatic vessels in vivo, which we have shown for the first time occur 
due to the contraction of the vessels in coordination with lymphatic valves creating the 
appearance of segmented flow of the dye.  Sinus regions appear constantly fluorescent 
while the remainder of the lymphangion only appears fluorescent during dilation periods, 
and although fluorescent values fluctuate in both segments of the lymphangion as packets 
travel along the vessel, the greatest changes in fluorescence occur between the sinus 
regions.  While our phantom does not contain these valves or the intrinsic mechanics that 
promote lymph transport, we have artificially reproduced this packet flow at a 
physiologically relevant depth in the phantom to quantify our system’s accuracy for 
measuring packet velocity in the presence of a scattering dermal layer and have 
demonstrated excellent accuracy in measuring velocity. Most NIR lymphatic imaging is 
performed giving an intradermal ICG injection and monitoring transport through dermal 
collecting vessels, which we have validated can be achieved with our device with a high 
degree of accuracy.  Future work to enhance the device should focus on the 
implementation of diffusion theory (e.g. using a Monte Carlo approach to predict light 
propagation through a tissue of known optical properties) to predict scattering effects and 
recreate a more accurate image of vessel geometry at various depths(131). 
Quantifying Functional Effects of NO on Lymphatics In Vivo 
 In this study we showed for the first time that immediate changes in lymphatic 
function resulting from the introduction of NO can be detected using non-invasive NIR 
lymphatic imaging.  Our findings, that GTNO significantly reduces lymphatic transport, 
corroborates existing knowledge that NO has an inhibitory effect on lymphatic pump 
function(72, 114, 198).  We have shown that NIR lymphatic imaging can provide real-
time in vivo measurements of lymphatic pump function in response to NO, which has 
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never previously been available, and may help to further elucidate the relationship 
between NO and lymphatic contractile regulatory mechanisms. The ability to measure 
this response non-invasively would be particularly useful given recent findings that 
certain immune cells migrate to the lymphatics and release NO as a means of regulating 
local lymphatic draining(114).  
 The gold standard for quantifying lymphatic pump function has been to utilize 
diameter tracking of contracting vessels to calculate parameters such as stroke volume 
and ejection fraction. These temporal traces of diameter changes have been achieved in 
isolated vessel preparations(71, 72), invasive in vivo intravital brightfield microscopy(26, 
54), and more recently through invasive intravital fluorescence microscopy using vessels 
filled with FITC labeled dextran(114). All of these approaches require invasive surgery to 
access and visualize the lymphatics, thus allowing for accurate diameter tracings. While 
the approach reported here has the advantage of being non-invasive, the scattering effects 
of the dermal layer and the lower frame rates do not currently provide the necessary 
spatial and temporal resolution to achieve accurate diameter tracings, which explains why 
this and other NIR lymphatic imaging systems have been unable to quantify these more 
traditional metrics of pump function. Thus we sought to define quantitative metrics of 
pump function similar to these parameters that could be calculated from our system, 
namely effective contraction length and systolic pumping power.  
 Effective contraction length describes, on average, how far a packet of fluid 
would travel down the lymphatic vessels before another contraction event is needed. 
Stronger contractions would propel fluid further (assuming that the immediate 
downstream valves are open), when compared to weaker contractions with lower ejection 
fractions. Systolic pumping power provides an estimation of the average power generated 
per unit mass by lymphatic pumping. A calculation of the actual power would require 
knowing the mass of the fluid packet, but this is difficult to estimate since accurate 
diameter measurements are difficult to achieve given the limitations of NIR imaging 
discussed above. It is likely that this mass would be different between treatment groups 
since it is known that NO increases the vessel diameter(72). However any changes that 
would occur in packet mass due to vessel dilation would be small (~2-fold increase) 
when compared to the changes seen in the power per unit mass parameter (~50-fold 
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decrease). Both of the new parameters developed here demonstrate the potential to 
describe remarkable differences in lymphatic pump function that could be difficult to 
capture when tracking packet frequency or velocity alone.   
 Our findings also have the potential to establish NIR lymphatic imaging as an 
early-stage lymphatic disease diagnostic.  To date, NIR imaging has been reported in the 
literature to be capable of identifying differences in lymphatic pump function between 
healthy states and several late-stage disease states(128, 209, 247).  However, given that 
most lymphatic disorders are characterized by a progressive deterioration of lymphatic 
pump function prior to the presentation of clinical manifestations, NIR imaging may be 
capable of detecting changes in lymphatic pump function in the very early stages of the 
disease before visible symptoms begin to present.  Our findings suggest that NIR imaging 
is very sensitive to detecting differences in lymphatic transport function and could be 
used as a screening mechanism for patients at a high-risk for developing lymphatic 
disorders, such as post-mastectomy breast cancer patients. In this way, corrective 
measures could be taken before irreversible tissue damage would occur, thus improving 
patient outcomes with lymphatic diseases. 
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CHAPTER 3: DIFFERENTIAL TRANSPORT FUNCTION OF 
LYMPHATIC VESSELS IN THE RAT TAIL MODEL AND THE 
LONG-TERM EFFECTS OF INDOCYANINE GREEN 
 
 Near-infrared (NIR) imaging has emerged as a novel imaging modality for 
assessing lymphatic function in vivo. While the technique has provided quantitative data 
previously unavailable, questions remain in regards to the spatiotemporal capabilities of 
the approach. We address three of the more important issues here using the rodent tail, 
one of the most widely utilized in vivo model systems in the lymphatic literature. 
Specifically we demonstrate 1) the transient vs. steady state response of lymphatics to 
tracer injection, 2) the functional characteristics of multiple collecting vessels draining 
the same tissue space in parallel, and 3) the long-term consequences of fluorescent tracers 
on lymphatic function to repeated functional measurements. 
 Rat tails were imaged with NIR and metrics of function were calculated 
for both collecting vessels that drain the tail. A nitric oxide donor cream (GTNO) was 
applied to the tail.  Additionally, two different NIR dyes, indocyanine green (ICG) and 
LI-COR IRDye 800CW PEG, were utilized for function imaging at the time of initial 
injection and at 1, 2, and 4 week follow-up time points after which both draining lymph 
nodes were harvested. 
 Significant differences were found between the two collecting vessels such that 
the vessel first showing fluorescence (dominant) produced enhanced functional metrics 
compared to the second vessel (non-dominant). GTNO significantly reduced lymphatic 
function in the non-dominant vessel compared to the dominant.  ICG remained visible in 
the tail for 2 weeks after injection and was accompanied by significant losses in 
lymphatic function and enlarged draining lymph nodes. The Licor tracer also remained 
visible for 2 weeks. However, the dye produced significantly lower effects on lymphatic 
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function than ICG, and lymph nodes were not enlarged at any time point, suggesting that 
this may be a more appropriate contrast agent for longitudinal lymphatic imaging.  
Introduction 
The lymphatic vasculature is present in nearly every tissue of the body to serve 
essential functions in fluid homeostasis (57, 156), immune cell trafficking (230, 265), and 
lipid transport (56), and it has been implicated in the progression of several diseases (189, 
240).  Despite the critical roles that this system performs, very little is known about the 
lymphatic vasculature in comparison to the blood vasculature, which can be attributed, in 
part, to the historic difficulty associated with imaging lymphatic vessels(212).  With the 
growing interest in studying lymphatics, near-infrared (NIR) imaging has emerged as a 
novel lymphatic imaging modality to simultaneously improve spatial resolution to 
visualize small initial lymphatics and increase temporal resolution to capture the dynamic 
lymphatic pump function responsible for fluid propulsion.   
 To date, NIR lymphatic imaging has produced exciting results quantifying 
lymphatic transport (181), illustrating differences in lymphatic architecture between 
normal and severe disease cases (247), showing differences in function and architecture 
due to genetic mutation (34), and assessing changes in lymphatic function in response to 
various manipulations (29, 268).  However, the technique remains immature, and the 
field is still learning to understand and interpret the wealth of data NIR functional 
lymphatic imaging can uniquely provide compared to other modalities.  In particular, 
recent work has suggested functional differences between two collecting vessels in a 
rodent hind limb (171), but no studies have specifically examined the differential 
transport abilities of multiple collecting vessels draining a single tissue space.  Such an 
analysis is a necessary advancement of NIR functional lymphatic imaging, which has 
historically focused on quantification of only a single vessel, to better understand the 
physiology of draining lymphatic networks at the tissue level. 
 Therefore, we have chosen to simultaneously characterize the two collecting 
vessels in the rat tail model using NIR lymphatic imaging.  The rat tail provides the 
simplest model of lymphatic network drainage for NIR imaging purposes due to the 
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simple geometry and the consistent position of the two collecting vessels.  Using the 
rodent tail also allows comparisons to many previous studies as it has been one of the 
most widely used models in lymphatic research, providing insight into basic lymphatic 
physiology and lymph flow (111, 268), lymphangiogenesis (30, 42, 78, 276), and 
lymphedema pathology (195, 237, 279). The results of this characterization will establish 
a framework by which future lymphatic research can be performed using NIR imaging in 
the tail model and will enhance our understanding of differential vessel function. 
 Additional controversy also remains regarding the most appropriate fluorophore 
for NIR lymphatic imaging.  Some studies are beginning to explore novel probes with 
higher quantum yields that specifically target lymphatic vessels (47, 171, 173), but the 
most commonly used probe to date has been indocyanine green (ICG).  Despite the low 
quantum yield of the molecule, ICG remains the hallmark of NIR lymphatic imaging 
because it is FDA approved for use in humans and represents the most likely probe for 
the development of a point-of-care diagnostic.  However, the literature is mixed regarding 
the effects of ICG on lymphatic function.   
 It has been shown in isolated lymphatic vessels that ICG inhibits vessel 
contraction in a dose-dependent manner and continues to alter function even beyond 
complete washout from the vessel (73).  Given that near-infrared fluorophores have been 
shown to accumulate in the intracellular space (69), and ICG, in particular, has been 
shown to exhibit extremely cumulative cellular uptake (1, 62), we hypothesize that ICG 
is retained in the tissue space and contributes to a decrease in lymphatic function for an 
extended period of time following initial injection.  A follow-up study using NIR imaging 
was unable to detect changes in lymphatic function after ICG injections of various 
concentrations (5), but the study only examined this phenomenon at one time point.  
Therefore, in this study we will first examine the retention of ICG in the tissue space of 
the rat tail and measure lymphatic function with NIR imaging beyond the duration of 
retention to analyze the time course changes in lymphatic function following initial ICG 
injection.  For comparison purposes, we will also perform this analysis with a competing 
NIR fluorophore, the LI-COR IRDye 800CW PEG.  The results of this study will 
contribute to a further characterization of the rat tail model for NIR lymphatic imaging 
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and will inform future studies involving multiple, repeat injections of NIR probes in this 
model. 
Hypotheses 
Aim 2 Hyopotheses 
H2.1:  When multiple collecting vessels drain the same tissue space, they will have 
heterogeneous transport capacities, and may exhibit a differential response to stimuli. 
H2.2:  Lymphatic transport as measured through NIR imaging will vary as a function of 
time after initial injection due to the transient alteration in interstitial fluid pressure 
resulting from the bolus injection. 
H2.3: ICG has a time-delayed effect on lymphatic function such that it will decrease 
lymphatic transport capacity in the context of time-course experiments with repeat 
fluorophore injections.  Specifically: 
H2.3.1: ICG remains present in the tissue space for an extended period of time 
following a bolus injection for NIR lymphatic imaging. 
H2.3.2: ICG will cause a reduction in lymphatic function in a time-delayed 
manner such that repeat measurements at later time-points will exhibit significant 
reductions in NIR lymphatic measurements.  This time-course of reduced 
lymphatic function may correlate with the retention of ICG in the tissue space. 
H2.3.3: ICG will demonstrate evidence of inflammation that will correlate with 
retention of the dye in the tissue space.  
Methods 
Hardware Configuration 
NIR imaging hardware (Figure 18-A) consisted of a 150mW 808nm laser diode 
(Thorlabs part no. M9-808-0150) powered by accompanying diode driver and 
temperature control boxes to provide excitation light.  A 20° beam diffuser (Thorlabs part 
no. ED1-C20) was mounted in front of the diode to achieve a uniform excitation field.  
Fluorescence emission centered at 840 nm was captured using a PIXIS 1024B back-
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illuminated CCD camera (Princeton Instruments) with an attached Infinity K2/SC video 
microscope lens (Edmund Optics) and a bandpass filter (CW:840 nm, FWHM:15 nm, 
Omega Optical).  NIR images were recorded via a custom LabVIEW (National 
Instruments) image acquisition code. 
NIR Imaging Procedure 
Lymphatic function was quantified in vivo in the tail of six-week-old female 
Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) according to 
procedures approved by the Georgia Institute of Technology IACUC Review Board and 
performed in our laboratory previously (268).  All animals were first anesthetized using 
an intramuscular injection of Fentanyl (0.12 mg/kg), Droperidol (6 mg/kg), and 
Diazepam (2.5 mg/kg given 10 minutes after Fentanyl/Droperidol).  A 10 µL fluorophore 
solution of either ICG (Across Organics) pre-mixed with bovine serum albumin (BSA) 
(MP Biomedicals, New Zealand) at a concentration of 150 µg/mL ICG and 60 mg/mL 
BSA or LI-COR IRDye 800CW PEG was then injected intradermally into the tip of the 
tail for fluorescence imaging (Figure 18-B). An injection volume of 10 µL was chosen 
based upon past success in rodent models, so as to not overload the lymphatics with 
unnecessary fluid volume while at the same time providing enough tracer for sufficient 
detection (108, 268).  The injection was given at an entry angle of approximately 10 
degrees to an approximate depth of 1 mm to specifically target the lymphatic vasculature. 
Care was taken to position the injection as close to the midline of the tail as possible to 
avoid favoring one collecting vessel over the other.  The excitation source and the field of 
view of the CCD emission detector were centered on the rats’ tail 10cm downstream 
(towards the base of the tail) from the injection site at the tip of tail (Figure 18-C). This 
location ensured that only the downstream collecting lymphatics would be visualized so 
as to avoid any potential complications from fluorescence uptake by initial lymphatics. 
The small volume of fluid injection and the use of NIR to enhance tissue penetration 
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ensures that only fluorescence in the deeper collecting lymphatics is visible downstream 
of the injection site.  The animals were imaged continuously from the time of injection 
until 20 minutes post-injection with a 50ms exposure time.   
 
Figure 18: Near-infrared lymphatic imaging setup. (A) Schematic of near-infrared imaging 
hardware.  (B) Intradermal tail injection of near-infrared fluorophore.  (C) Example of imaging 
window 10 cm proximal to injection site showing fluorescence uptake in the two collecting lymphatic 
vessels. 
Quantifying Lymphatic Function 
To evaluate lymphatic function, three parameters were measured: the time 
necessary for the bolus injection of ICG to travel the 10 cm distance from injection site to 
emission recording site (transport time), the average velocity of the packets traveling 
through the field of view of the recording site, and the average frequency of packets 
passing through the field of view according to previously published methods (268).  In 
order to characterize the individual function of the two collecting lymphatic vessels of the 












metrics were separately calculated for the two vessels of the tail.  For the purposes of this 
analysis, the vessel in which fluorescence first arrived (marked by a 20% increase in 
intensity) was defined as the dominant vessel and the other vessel was defined as non-
dominant.  An example of intensity plots in the two vessels can be seen in Figure 2A.  To 
evaluate differences in the transient response to fluid injection from the steady state 
response, lymphatic function metrics were calculated in two separate 100-second 
segments after injection: the arrival segment beginning 60 seconds after fluorescence 
arrival in each vessel and the steady state segment beginning 10 minutes after injection.  
A representative example of the functional metrics calculated for both segments in a 
healthy animal is shown in Figure 2B-E.  A paired, two-tail t-test with a Bonferonni 
correction for multiple comparisons was used to test for significance with α = 0.05. 
Lymphatic Imaging in Response to Nitric Oxide Treatment 
A nitric oxide (NO) donor cream (glyceryl trinitrate ointment, GTNO) was 
applied to the tail as a second experimental condition to observe the effects of NO on the 
lymphatic function metrics of the two vessels (n=3).  GTNO was applied to the whole tail 
one-minute prior to injection.  Lymphatic function was calculated for both collecting 
vessels in the same manner described above.  Comparisons between normal and GTNO-
treated animals were checked for significance using an unpaired, two-tail t-test with a 
Bonferroni correction and α = 0.05.  Significance within the GTNO treatment group was 
analyzed using a paired, two-tail t-test with a Bonferroni correction and α = 0.05.  
Time-course analysis of ICG 
 To characterize the long-term effects of ICG on lymphatic function, a time course 
study was performed.  Initially, a single 10 µL intradermal ICG injection (150 µg/mL 
ICG and 60 mg/mL BSA) was given in the tip of the tail (n=4) and fluorescence 
measurements were taken every two days to track ICG retention. 
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 Based upon the results of the retention study, a second study was performed to 
monitor changes in lymphatic function during the ICG retention period, which is depicted 
graphically in Table 1.  All animals in this group were given an initial 10 µL intradermal 
ICG injection (150 µg/mL ICG and 600 mg/mL BSA) in the tip of the tail at week 0 and 
baseline lymphatic function measurements were recorded for both collecting vessels. 
 The animals were divided into three treatment groups with follow-up 10 µL 
intradermal ICG injections and functional measurements at 1, 2, and 4-week time points 
(n=4).  Follow-up injections were given as close to the original injection site as possible 
with particular care to keep the injection at the midline of the tail.  Definitions of 
dominant and non-dominant vessels were made based upon week 0 measurements and 
remained consistently defined throughout follow-up screenings regardless of follow-up 
transport times (although the dominant vessel continued to produce the fastest transport 
times in nearly 90% of cases).  Control animals were given a 10 µL intradermal BSA 
injection in the tip of the tail at week 0 with follow-up 10 µL intradermal ICG injections 
and functional measurements at the same three time points (n=4).  Comparisons of 
function between time points was checked for significance using a paired, one-tail t-test 
with α = 0.05. 
 A third set of animals was used to observe the effects ICG on lymph node size.  
All animals were again given a single 10 µL intradermal ICG injection in the tip of the 
tail.  The sciatic lymph node (nearest draining node) was harvested for both collecting 
vessels without any additional follow-up injections at the week 0, 1, 2, and 4 time points 
(n=3).  Control animals were given a 10 µL intradermal BSA injection in the tip of the 
tail and lymph nodes were harvested at each time point (n=3) without any follow-up 
injections. Lymph node size was calculated using projected two-dimensional area from 
microscopy images.  We attempted to take fluorescence images to observe ICG retention 
in the nodes, but fluorescence was only detectable at the week 0 time point.  Comparisons 
of lymph node size were checked for significance using an unpaired, two-tail t-test with a 
Bonferroni correction and α = 0.05. 
 In order to compare the results of ICG to another popular NIR fluorophore, the 
same procedure outlined above was also performed using the LI-COR IRDye 800CW 
66 
PEG including retention (n=4), time course functional measurements (n=4), and lymph 
node harvesting (n=3). 
Table 1: ICG Time-Course Experimental Setup.  Animals were divided into three groups for follow-
up imaging at 1, 2, and 4 weeks.  All animals were given a 10 µL intradermal injection of either ICG, 
IR Dye, or BSA at week 0, and function metrics were recorded as a baseline for treatment animals.  
During the follow-up session for each group, the animals were given a 10 µL fluorophore injection 
for lymphatic function measurements and lymph nodes were harvested. 
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Results 
Spatial and Temporal Characterization of Lymphatic Function in the Tail 
 Figure 19 shows a representative example of fluorescence intensity measurements 
over time and packet frequency and velocity measured during the arrival and steady-state 
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segments.  We have denoted the first arrival vessel as dominant and the other as non-
dominant.  All imaging sessions showed at least a 2 second difference in fluorescence 
arrival times between the two vessels with greater than 70% of cases showing a 
difference of 20 seconds or more. The dominant vessel nearly always produced higher 
intensity values than the non-dominant vessel throughout the imaging session (Figure 19-
A) and remained consistent across multiple injections in the majority of animals.   
 
Figure 19: Representative vessel transport characteristics. (A) Representative data set showing 
fluorescence over time for dominant and non-dominant vessel.  Arrival and steady-state segments are 
highlighted in the gray boxes.  (B) Close-up view of intensity signal during arrival segment.  (C) 
Close-up view of intensity signal during steady-state segment.  (D) Packet frequency and packet 
velocity during arrival segment.  (E) Packet frequency and packet velocity during steady-state 
segment. 
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 During the arrival period the dominant vessel exhibited a rapid increase in 
fluorescence while the non-dominant vessel usually produced a more gradual rise in 
fluorescence.  Packet frequency and velocity in both vessels peaked during or shortly 
after the arrival stage. The values then tapered off towards a lower, constant value during 
the steady-state period with the dominant vessel constantly producing larger or equal 
frequencies and velocities than the non-dominant vessel (Figure 19 D-E and Figure 20).  
The dominant vessel produced significantly reduced transport times, and significantly 
increased packet frequencies and packet velocities compared to the non-dominant vessel 
in the arrival segment, but there were no significant differences in the three functional 
metrics between the two vessels in the steady-state pumping period (Figure 21).  Packet 
frequencies and packet velocities were significantly higher during the arrival stage than 
the steady-state period in the dominant vessel, but not in the non-dominant vessel. 
 
Figure 20: Representative packet frequency and velocity tracings. Representative data set showing 
(A) average packet frequency and (B) average packet velocity for the dominant and non-dominant 
vessel over time. 
Differential Effects of Nitric Oxide on Lymphatic Function 
 The application of GTNO significantly increased transport times in both vessels 
compared to healthy animals as we have reported previously (268), but a much larger 
increase was seen in the non-dominant vessel in which transport times increased nearly 6-
fold (Figure 21).  NO-mediated vessels also showed significantly decreased packet 
frequency and packet velocity in both vessels during the arrival period and in the non-
dominant vessel during the steady state period. 
Average Packet Velocity
















































Figure 21: Lymphatic function metrics in healthy and GTNO-treated cases.  Compiled data for (A) 
transport time, (B) packet frequency, and (C) packet velocity for the dominant and non-dominant 
vessel during arrival and steady-state segments in healthy and GTNO-treated animals (n=3). Error 
bars represent standard deviation.  * = p<0.01. 
Consequences of ICG Retention on Lymphatic Function 
 ICG remained visible (as defined by a signal to noise ratio greater than 3 dB) in 
the tissue space for more than two weeks after initial injection (Figure 22).  NIR 
lymphatic function measurements after follow-up ICG injections of 1 week showed 
significant reductions in all three lymphatic function metrics in both vessels during the 
arrival and steady state segments (Figure 23). Transport time remained significantly 
elevated in the non-dominant vessel at the week 2 time point.  Packet frequency and 
velocity likewise remained elevated in the non-dominant vessel at week 2, but only 
during the arrival period. No significant differences in function were observed at week 4.  
























































































Figure 22: ICG is retained in tissue space for 2 weeks. (A) Representative images of the tip of a rat 
tail at four time points: immediately following ICG injection (week 0) and 1, 2, and 4 weeks after 
injection.  (B) Average signal-to-noise ratio (SNR) of ICG in the tip of the rat tail (n=4).  Dotted line 
represents limit of detection at 3 dB.  Error bars represent standard deviation. 
 Lymph nodes were also significantly enlarged in both vessels at the 1 and 2 week 
time points with more than a 350% increase in projected two-dimensional area at week 1 
and almost a 200% increase at week 2 (Figure 24).  Lymph nodes harvested at week 4 
were not significantly enlarged from their baseline values.  Control animals did not 
produce significant differences in lymph node size at any time point. 
Week 0 Week 1 
Week 2 Week 4 
ICG Retention in Injection Site

















Figure 23: ICG reduces lymphatic function 1 and 2 weeks after initial injection. Compiled (A) 
transport time, packet frequency during (B) arrival and steady-state (C), and packet velocity during 
(D) arrival and (E) steady-state periods for dominant and non-dominant vessels during the four time 
points and for the control animals at week 1.  Error bars represent standard deviation.  * = p<0.05. 
 The LI-COR IRDye 800CW PEG likewise remained visible in the rat collecting 
lymphatics for approximately 2 weeks. However, the only function metric observed to be 
significantly different during the follow-up sessions was an increased transport time in 
the non-dominant vessel at week 1.  When compared with ICG, the LI-COR dye 
produced much less severe effects on lymphatic function at the week 1 and 2 follow-up 
time points (Figure 25).  The LI-COR dye produced a significantly lower percent change 








































































































































































































in transport time in both vessels at week 1 and in the non-dominant vessel in week 2 as 
compared to ICG.  Similarly for packet frequency, the LI-COR dye produced a 
significantly reduced change at the week 1 time point in both vessels and at the 2 week 
time point in the non-dominant vessel as compared to ICG.  Additionally, for packet 
velocity, the LI-COR dye produced a significantly reduced effect compared to ICG at the 
week 1 and 2 time points only in the non-dominant vessel.  Finally, the LI-COR dye did 
not produce any significant changes in lymph node size at any time point. 
 
Figure 24: Draining lymph nodes enlarge 1 and 2 weeks after ICG injection.  (A) Representative 
microscopy images of sciatic lymph nodes without injection, 1 week after BSA control injection, and 
1 and 2 weeks after ICG injection.  Grid squares = 25 mm2.  (B) Projected two-dimensional area of 
lymph nodes prior to injection, 1 and 2 weeks after ICG injection, and 1 week after control BSA 
injection.  Data is compiled for both sciatic lymph nodes at each time point.  Error bars represent 
standard deviation.  * = p<0.001. 
Discussion 
Vessel Transport Characteristics 
 The lymphatic vasculature is a complex network of interconnected vessels and 
nodes whose fluid transport capabilities are still not well understood at the tissue level.  
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collecting lymphatic vessels draining a single tissue space, which will help to explain 
how the organ system functions as a whole in the context of fluid transport.  We have 
provided a new framework for analyzing lymphatic function across multiple vessels to 
better assess cumulative lymphatic drainage of the interstitium.  This framework will 
make NIR imaging more sensitive to lymphatic function, which may prove useful in 
distinguishing subtle changes between health and disease in the context of lymphatic 
research and the development of a point-of-care diagnostic.   
 
Figure 25: LI-COR IRDye 800CW PEG reduces lymphatic function less than ICG. Percent change in 
(A) transport time, (B) packet frequency, and (C) packet velocity between initial measurement and 1 
and 2 week follow-up time points for ICG and LI-COR IRDye 800CW PEG.  Error bars represent 
standard deviation.  * = p<0.01. 
 Our results revealed that one vessel always produced fluorescence before the 
other with the difference in 10 cm transport time between the two vessels usually 
exceeding 20 seconds. In nearly every case, the first arrival vessel exhibited higher 
fluorescence intensity values, packet frequencies and packet velocities than the second 
arrival vessel, although both vessels consistently produced values in a range consistent 
with previously reported mesenteric lymph velocities (54, 98) and packet frequencies and 
velocities in rat tail lymphatics (268).  We defined the first arrival vessel as dominant and 
the second arrival vessel as non-dominant in an effort to describe the observed difference 
in function between the two vessels.  Importantly, the dominant vessel remained 
consistent across multiple injections in the same animal in the vast majority of cases, 
suggesting this phenomenon is repeatable and inherent to the function of that particular 
vessel network.  Similar differential transport characteristics were also observed by 
Proulx et al. in two afferent collecting vessels of the mouse hind limb (171), which 
indicates that our results may not be restricted to simply the rodent tail model and may be 
representative of general systemic lymphatic function. Future work will need to be done 
to address the relevance of these observations in rodents to human lymphatic physiology. 
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 There are several potential explanations for the observation of differential 
transport function between the two collecting vessels.  Firstly, it is possible that 
preferential lymphatic drainage patterns exist such that for a given tissue space, fluid 
drainage is the primary responsibility of one single vessel, while any additional vessels in 
the area serve as overflow or reserve transport routes for large fluid loads. Preferential 
drainage patterns could be the result of regional variability in the location and distribution 
of different lymphatic vessel networks in the tissue space or the composition and 
organization of the interstitium at the injection site such that drainage into one collector 
over is favored over the other. Since our repeat injections in the same animal were 
performed as close to the original injection site as possible, either of these two potential 
explanations could account for the consistency of the dominant vessel across multiple 
injections. Although the utmost care was taken to ensure all injections were consistently 
given at the same angle, depth, and location, there is a substantial degree of inherent 
variability in the intradermal injection procedure, which could also be contributing to the 
observed differences in vessel function by differentially or inconsistently favoring 
drainage into one vessel over another.  Furthermore, there were no detectable differences 
in vessel size within the spatial resolution limits of our imaging system, but fluorescence 
scattering makes accurate measurements of vessel diameter very difficult in vivo.  Thus, 
it remains unclear whether subtle differences in vessel depth or vessel diameter may be a 
contributing factor favoring transport through one vessel over the other.  Finally, the 
degree to which nodal resistance may contribute to the observed results is unknown and 
could be significant.  Future work should specifically focus on the differences in function 
between multiple lymphatic vessels in several anatomic regions and under various 
experimental conditions to better characterize systemic lymphatic transport. 
 Our results also revealed a transient period during early fluorescence arrival in 
which lymphatic function was generally enhanced as compared to the subsequent steady-
state period.  This observation is not surprising when considering the bolus delivery and 
high albumin concentration of our injection. The duration of the transient arrival period 
was typically between 2 - 5 minutes, which is consistent with the small 10 µL volume of 
our injections and the time kinetics associated with responses to changes in Starling’s 
forces observed in the microvasculature (113).  After the initial response of the 
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lymphatics to this change in the local interstitial fluid parameters that govern filtration, 
steady-state values of lymphatic transport were reached. Interestingly, more significant 
differences in function were observed between the dominant and non-dominant vessel 
during the transient arrival period than the steady-state period.  This is consistent with the 
method we have utilized to categorize these two vessels (i.e. the vessel with a shorter 
arrival time is the dominant), as the arrival time is a metric that is reflective of vessel 
function during the initial transient response. Thus the larger packet velocities and 
frequencies in the dominant vessel immediately after injection explain in part why 
transport time is shorter than in the non-dominant vessel.  
 These observations generally illustrate the importance of using a consistent 
framework to quantify lymphatic vessel function using NIR imaging. That is, we have 
shown that significant differences in transport characteristics are obtained by taking 
measurements during different periods following fluorophore injection or by quantifying 
different vessels draining the same tissue space.  An optimal strategy for NIR 
quantification of vessel function remains undefined at this point, but future studies should 
be performed with careful consideration of the measurement framework, especially given 
that the selection of methodology for analysis can drastically affect results. 
Effects of Nitric Oxide 
 The effects of NO on vessel function further exemplify the importance of 
choosing an appropriate framework for transport quantification using NIR imaging.  Our 
previous work showed that GTNO significantly reduced lymphatic drainage as evaluated 
by several function metrics (268), but that analysis was limited to a single vessel and 
response time.  Analyzing the effects of GTNO in the context of this more robust two-
vessel, two-time-period framework may begin to provide a more broad understanding of 
the effects of NO on cumulative lymphatic drainage.  Specifically, the results indicated 
that GTNO generally reduced function in both vessels, but more severely affected the 
non-dominant vessel.   
 The transport time metric, in particular, was very different between the two 
vessels after GTNO application.  This metric incorporates extrinsic factors affecting 
uptake such as interstitial fluid pressure and matrix resistance as well as intrinsic factors 
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affecting transport such as vessel contraction.  Given that previous work has shown NO 
acts on lymphatics by strongly inhibiting vessel contractility (72, 114), these results could 
suggest a difference between the two vessels in the balance of intrinsic contractions 
versus extrinsic factors in fluid transport following a large fluid load.  That is, if 
preferential drainage patterns exist as we suspect, the increased interstitial fluid pressure 
after bolus injection would drive flow more favorably into the dominant vessel, while the 
non-dominant vessel would be forced to rely more exclusively on intrinsic contractions to 
transport fluid. The resultant vessel dilation following GTNO application would severely 
impair transport in the non-dominant vessel by inhibiting contractility.  However, the 
effects would be much less severe in the dominant vessel because dilation would 
decrease vessel resistance, thus enhancing the effects of elevated interstitial fluid pressure 
driving flow into the vessel.  This could help to explain why NO more significantly 
affected the non-dominant vessel, especially in the transport time metric. 
 Alternatively, these observations could be the result of secondary effects of NO 
on lymph formation, which could differentially affect uptake and subsequent transport in 
the two vessels. The lymphatic community has recently become very interested in the 
modulating effects of NO on lymphatic function in health and disease (32, 114, 201), and 
future work devoted to a more thorough characterization of NO on lymphatic network 
drainage would be well-warranted. 
Effects of NIR Fluorophores 
 In this study, we have shown for the first time with NIR imaging that injection of 
ICG contributed to long-term decreases in lymphatic function.  The results of the long-
term follow-up screenings revealed that ICG was retained in the local tissue space for 
approximately two weeks after injection, and lymphatic transport was reduced during this 
period.  There was a fairly dramatic decrease in function at the 1 week time point in 
which all metrics were reduced in both vessels, but week 2 produced a less severe 
reduction in function and was limited exclusively to the non-dominant vessel.  Lymph 
nodes were also enlarged at 1 and 2 weeks after injection, but interestingly, there was not 
a significant difference in size between lymph nodes of the dominant and non-dominant 
vessel.  Very importantly, control animals in which the initial injection contained albumin 
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but lacked ICG did not produce any significant change in function or lymph node size at 
any time point.  Since the control injections were the same volume and given in the same 
manner as the ICG injections, this data suggests that the observed decreases in lymphatic 
function following initial injection of ICG were due to the fluorophore itself rather than 
the injection procedure or any other constituent of the injection solution. 
 Fortunately, the effects of ICG appear to be reversible since all of the functional 
metrics returned to baseline levels in both vessels and lymph nodes returned to normal 
size at the week 4 time point.  Despite the data showing a functional decrease in 
lymphatic transport after ICG injection, it is difficult to determine whether the observed 
effect sizes are substantial enough to warrant physiological concern. Although lymph 
nodes showed signs of enlargement after ICG injection, the level of hypertrophy was not 
nearly as large as the 20- to 30-fold increase in nodal weight seen in models of chronic 
inflammation (20, 61).  No detectable edema was observed in the tail of any of the 
animals at any point during the time course, which suggests that ICG does not decrease 
lymphatic drainage to the point of causing significant fluid stagnation or inflammation.  It 
does not appear that ICG needs to be treated as a health concern at least at frequencies 
that don’t exceed once per month, but care should be taken in interpreting NIR functional 
data with this fluorophore, especially in the context of repeat injections.  Repeat 
injections with ICG may need to be spaced as far apart as 4 weeks in order to avoid 
erroneous measurements in function, although a similar investigation of time-course 
effects of ICG in humans would be valuable for the continued development of a point-of-
care diagnostic. 
 The observed decreases in lymphatic function are consistent with the investigation 
of ICG in isolated lymphatic vessels by Gashev et al. (73).  Our result, that reduced 
function appeared to coincide with ICG retention, is similar to their observation that 
vessel contraction was inhibited even beyond the period of ICG washout.  Gashev et al. 
was able to show ICG binds to the endothelial cell layer in the isolated vessel setup, but 
in our study, ICG was most visibly retained at the injection site. A small amount of 
fluorescence was visible in the collecting vessels for 1-2 days immediately after the 
injection, but the intensity quickly dropped below the limit of detection due to scattering 
effects and a low concentration of dye.  With our imaging system the limit of detection of 
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ICG in tail collecting vessels is in the micromolar range, which is consistent with 
concentrations used by Gashev et al.  It is difficult, therefore, to make strong conclusions 
from our data regarding the mechanism by which ICG affected lymphatic function.  At 
the very least, however, the injection site would have been constantly releasing small 
amounts of ICG into the lymphatic vessels over the course of the retention period, which 
could have contributed to the long duration of decreased function. Given the evidence of 
ICG toxicity with prolonged exposure in the retina (90), it is possible that the decrease in 
lymphatic function could also be a result of ICG reported mild toxicity.  
 One limitation of our study is that we only used one concentration of ICG for 
injection.  Although the volume of the injection is very small, the concentration is 
optimized for fluorescence visualization rather than consideration of vessel function.  It is 
possible that a more dilute solution, while negatively influencing fluorescence intensity, 
may contribute to shorter retention periods and have less of a long-term impact on 
function. 
 An additional investigation by Aldrich et al. did not detect a change in lymphatic 
function in response to ICG injections (5), but these results do not necessarily conflict 
with ours and there are several explanations for these results.  Firstly, it should also be 
noted that our initial baseline readings for ICG and the LI-COR IRDye 800CW are 
similar to those reported by the authors.  The principal difference between the two studies 
is the time-point of interest after injection.  Aldrich et al. examined lymphatic function 
effects immediately after injection while we used this value as a baseline and instead 
focused on time course differences 1, 2, and 4 weeks later. Given that ICG has been 
shown accumulate in the intracellular space for a period beyond 24 hours (1, 62), time 
may be a necessary component for the cumulative dose to affect vessel function.  Another 
difference between our study and that of Aldrich et al. is the above-mentioned framework 
used for analysis of NIR imaging.  This framework was critical to generating our results, 
especially since more profound effects were seen in the non-dominant vessel and during 
the arrival period initially after injection.  Finally, our study was performed in the rat tail, 
while Aldrich et al. used the mouse inguinal-to-axillary model, and it remains unclear if 
and how lymphatic function may vary between the two regions and the two species.   
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 The functional results of the LI-COR IRDye 800CW PEG provide an interesting 
comparison to ICG.  The dye produced a mild decrease in lymphatic function at week 1, 
but it did not contribute to a deterioration of function nearly as severe as ICG and did not 
affect lymph node size.  These results are not meant to indicate that the LI-COR IRDye is 
an optimal solution for NIR lymphatic imaging, although it appears to have less of a 
long-term effect on lymphatics than ICG, but rather to illustrate that the choice of 
fluorophore impacts NIR lymphatic functional measurements. Thus, optimizing the tracer 
of choice to minimize its biological impact is warranted, particularly in the context of 
longitudinal lymphatic imaging.  The difference in functional response between ICG and 
the IRDye may suggest that the chemical composition and three-dimensional structure of 
the fluorophore either directly modulates lymphatic transport or indirectly affects 
lymphatic function through eliciting an immune response (114), especially given the 
observed differential effects on lymph node size between the two dyes in this study.  The 
NIR lymphatic imaging community has been directing research towards the development 
and optimization of fluorophores specifically for the purpose of lymphatic imaging (47, 
171, 172).  While these efforts have concentrated primarily on using dyes with higher 
quantum yields than ICG or altering the size of the carrier molecule to optimize 
lymphatic uptake, future work in the development of new probes should also focus on the 
long-term effects of the dyes on local lymphatic and immune function.  Repeat injections, 
either in the context of research or a point-of-care diagnostic will need to have no effect 
on lymphatic function in order to obtain meaningful and consistent results. 
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CHAPTER 4: NEAR-INFRARED IMAGING ANALYSIS OF 
LYMPHATIC FUNCTION IN LYMPHEDEMA 
 Introduction 
 More than 130 million individuals worldwide suffer from lymphedema, a chronic 
disease that presents with the accumulation of fluid, proteins, and adipocytes in the 
interstitium, resulting in in a drastic enlargement of the affected limb(186, 187).  The 
most common form is secondary (acquired) lymphedema, which results from the 
disruption of previously normal lymphatic networks, usually through injury or surgical 
procedure(233). In developed countries, the two main contributors to secondary 
lymphedema are surgical and radiotherapeutic cancer interventions, with breast-cancer 
related lymphedema being the most encountered and studied form(188).  Surprisingly, 
most secondary lymphedema cases present 1-3 years or more after the insulting event, 
rather than immediately following the trauma(187).  It is this latency period that makes 
lymphedema so difficult to diagnose early and treat effectively.  Despite the prevalence 
of the disease, there is very little known about the exact mechanisms of disease 
progression, especially as it relates to lymphatic transport function and the progressive 
loss thereof. 
 It remains unclear how the response of the lymphatic system during the post-
trauma period contributes to the onset of lymphedema, which has severely limited our 
ability to understand the disease mechanism and cascade.  It is well documented that the 
injury or surgical wound space forms into scar tissue, which subsequently limits new 
lymphatic vessel growth in the space and hampers interstitial fluid flows(13, 164, 221, 
253, 263).  There is also evidence that an inability of the lymphatic system to adequately 
regenerate during normal wound repair may predispose the tissue to swell during 
secondary lymphedema(164, 253).  However, one study found that the resolution of acute 
lymphedema through the recovery of functional fluid drainage was not inhibited by 
VEGF-R3 neutralization, which suggests that lymphangiogenesis did not contribute to 
the lymphedema recovery(135).  It has been shown that accumulating lymph may 
experience compensatory drainage through a reduced number of surviving local 
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lymphatics, rerouted lymphatics that bypass the obstructive tissue, or lymphovenous 
communications(144, 219). Additionally, inflammation has been shown to contribute to 
the degree of swelling in lymphedema(150, 279, 281) and may influence the appearance 
and perpetuation of the swelling(136). 
 Since lymphatic flow is driven primarily through the contractility of collecting 
lymphatic vessels, the ability to quantify lymphatic pump function through the imaging 
of functional lymphatic transport in the context of early lymphedema onset would greatly 
enhance our understanding of the disease progression.  We hypothesize that lymphedema 
is associated with a progressive loss of lymphatic function, which can be visualized and 
subsequently quantified with NIR imaging, thus affording novel insights into the disease 
cascade.  The latency period commonly associated with lymphedema, in particular, 
motivates a hypothesis of remodeling-induced lymphatic failure, which has begun to 
gather support in the literature(136).  Importantly, however, all of the animal models 
reported in the literature to date have severed all of the collecting vessels draining the 
tissue space of interest, and the analysis has focused exclusively on morphological 
changes occurring in the dermal layer and functional changes occurring in the initial 
lymphatics.  No study to date has investigated the changes in collecting vessel function 
associated with lymphedema, and no model currently exists that allows preservation of 
collecting vessel trunks. 
 Therefore, we will develop a new rodent tail model of lymphedema allowing for 
selective preservation of certain lymphatic collectors in order to track changes in the 
collecting vessel transport metrics over time using NIR lymphatic imaging.  We will take 
baseline NIR functional measurements before surgery, immediately after surgery, and in 
regular follow-up intervals to record changes in collecting vessel transport function.  The 
goal is to develop a model that exhibits similar pathological progression as the classic 
rodent tail model of lymphedema while preserving a single intact collecting vessel trunk.  
Doing so will provide the first opportunity to study the link between lymphedema 
progression and lymphatic transport as well as help to generate new insights into the 
potential mechanisms of lymphatic failure during disease progression. 
 Critical to tracking the progression of lymphatic function through the disease 
cascade in this study will be the use of the effective lymphatic pumping pressure metric, 
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which was first developed by Unno et al. and recently adapted for high precision 
measurement in rodent tails by our laboratory(152, 248).  The technique measures the 
pressure required to occlude the vessel and is indicative of the pumping capacity of the 
vasculature.  This will be the first study to apply such a robust set of metrics towards the 
assessment of lymphatic transport function in the context of lymphedema, which will 
begin to provide a wealth of new knowledge regarding the specifics of lymphatic 
pumping capacity associated with the disease. 
Hypotheses 
H3.1: Ligating the mouse tail such that one lymphatic collector remains intact will create 
a pathological model of lymphedema while simultaneously allowing NIR functional 
metrics to be obtained from the intact vessel.  The tails may exhibit slightly less swelling 
than the standard full ligation tail model. 
H3.2: Ligating the dominant vessel will produce significantly increased swelling as 
compared to ligation of the dominant vessel. 
H3.3: Swelling will correlate with reductions in lymphatic function as quantified through 
NIR lymphatic imaging. 
H3.4: The disease cascade will contribute to remodeling of the intact collecting vessel 
such that the pumping capacity is reduced. 
Methods 
Surgical Model and Time Course Measurements 
 The rodent tail model of lymphedema has been used extensively in previous 
studies(13, 40, 195, 253, 279).  Generally, a dermal-layer incision is made spanning the 
entire circumference of the tail such that all collecting and capillary lymphatics are 
severed.  This technique produces a well-documented swelling cascade that closely 
resembles the progression of lymphedema, at least in the dermal layer.  
 In an attempt to study the role of collecting lymphatic vessel function in 
lymphedema onset and progression, we modified the conventional tail lymphedema 
model.  Specifically, we altered the dermal incision such that it spanned nearly the entire 
83 
circumference of the tail with the exception of allowing one collector to remain intact 
(Figure 26).   
 
Figure 26: Example NIR Image of Tail Ligation Technique.  This NIR image shows the collecting 
vessel intact on the bottom and the severed vessels on the top.  The severed vessels force lymph to 
travel laterally across the tail through the interstitial space and capillary network to reach the intact 
collector for transport. 
 Previously, our group has characterized the lymphatic physiology of the tail as 
having a dominant and a nondominant collecting trunk(267).  The present study included 
three experimental groups: (1) a vessel ligation group in which the dominant vessel was 
ligated (n=4), (2) a vessel ligation group in which the nondominant vessel was ligated 
(n=4), and (3) a sham control group in which both collecting vessels were left intact 
(n=4). Eight-week-old female balb-c mice (Charles River Laboratories, Wilmington, 
MA) were used for this study according to procedures approved by the Georgia Institute 
of Technology IACUC Review Board.  All animals were first anesthetized using inhaled 
isofluorane (5% induction, 2% maintenance). All three groups received incisions 1 cm 
from the base of the animal spanning 80-90% of the circumference of the tail with 
particular care to standardize the incisions as much as possible.  In the vessel ligation 
groups, the incision severed one collecting vessel and left one intact, while in the sham 
control group the incision severed a substantial percentage of the lymphatic capillary 
network, but none of the collectors were severed. All incisions were cauterized to prevent 
bleeding and fluid leakage.  After the surgical procedures, both collecting vessels were 
NIR Image Brightfield Image 
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checked with NIR imaging to ensure they were either severed or remained intact as 
appropriate.  Animals in which vessels were improperly ligated or in which blood vessels 
were ligated were excluded from the study. 
 Baseline metrics were collected in all groups prior to surgery.  NIR functional 
metrics were again measured after surgery at 2 day, 4 day, 1 week, 2 week, 3 week, and 3 
month time points (Figure 27).  Tail measurements were taken every two days via two-
dimensional projected area to track swelling progression.  Lymphatic pumping pressure 
measurements were taken before surgery and at 2 day, 4 day, 1 week, and 3 month time 
points.  All animals were euthanized after 3 months, and tissue samples were harvested 
including cross-sectional tail samples, draining lymph nodes, and excised collecting 
vessels. 
 
Figure 27: Experimental time-course.  Baseline measurements were performed before surgery and 
routinely after surgery for three weeks, and then a final measurement was made at 3 months.  Tails 
were measured every two days for four weeks. 
NIR Functional Imaging 
 NIR lymphatic imaging was performed according to previously published 
methods(152, 267, 268).  Briefly, lymphatic function was quantified in vivo in the tail of 
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according to procedures approved by the Georgia Institute of Technology IACUC 
Review Board and performed in our laboratory previously (268).  All animals were first 
anesthetized using inhaled isoflurane (5% induction, 2% maintenance).  10 µL of LI-
COR IRDye 800CW PEG (LI-COR Biosciences, Nebraska, USA) was then injected 
intradermally into the tip of the tail for fluorescence imaging (the fluorophore was 
reconstituted according to manufacturer instructions for lymphatic imaging). An injection 
volume of 10 µL was chosen based upon past success in rodent models, so as to not 
overload the lymphatics with unnecessary fluid volume while at the same time providing 
enough tracer for sufficient detection (108, 268).  The injection was given at an entry 
angle of approximately 10 degrees to an approximate depth of 1 mm to specifically target 
the lymphatic vasculature. Care was taken to position the injection as close to the midline 
of the tail as possible to avoid favoring one collecting vessel over the other.  The 
excitation source and the field of view of the CCD emission detector were centered on 
the mouse’s tail 7cm downstream (towards the base of the tail) from the injection site at 
the tip of tail . This location ensured that only the downstream collecting lymphatics 
would be visualized so as to avoid any potential complications from fluorescence uptake 
by initial lymphatics. The small volume of fluid injection and the use of NIR to enhance 
tissue penetration ensures that only fluorescence in the deeper collecting lymphatics is 
visible downstream of the injection site.  The animals were imaged continuously from the 
time of injection until 20 minutes post-injection with a 50ms exposure time.  Analysis of 
NIR functional metrics was performed during the steady-state period ranging from 5-20 
minutes after injection, as defined previously(267). 
 NIR functional measurements included a combination of previously reported 
metrics and newly developed metrics for this model.  Packet frequency, emptying rate, 
pumping pressure and fluorescent tail area were measured and recorded as previously 
published(152, 268).  Transport time was used to determine the identity of the dominant 
and nondominant collector, but was not used during time-course analysis of lymphatic 
function.  Packet velocity was also not used for functional analysis because the dynamics 
of mouse contractile function, especially in the diseased cases, prevented reliable velocity 
measurements.   
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 A new NIR functional metric was developed called Lymphatic Flourescence 
Transport.  Packets were detected by first identifying peaks in the fluorescence signal and 
then identifying the time points at which troughs on either side of the peak occurred 
(Figure 28).  The fluorescence signal was then integrated across each packet and summed 
over the length of the data set.  Lymphatic fluorescence transport was then calculated as 
the time-normalized sum of the packet integrals such that: 
𝐿𝑦𝑚𝑝ℎ𝑎𝑡𝑖𝑐  𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒  𝑇𝑟𝑎𝑛𝑠𝑝𝑜𝑟𝑡 =   




, where n is the number of 
packets in the data set and f(t) is the fluorescence signal within each packet region 
(between the minimum and maximum time points corresponding to each packet).  This 
metric represents the cumulative transport of fluorescence through the vessel normalized 
by time and was used to assess overall lymphatic transport capacity.  Average packet 
amplitude was also measured and recorded to assess contractile function of the vessels. 
 
Figure 28: NIR lymphatic transport.  This is an example plot of fluorescence over time in a region of 
interest in a collecting vessel.  The packet integral was calculated by first defining the spikes in 
intensity corresponding to packets and then integrating the signal in these regions.  Lymphatic 















 In order to introduce an immune challenge, oxazolone (Sigma, catalog number 
E0753) was applied to the tails of dominant ligation and sham animals according to 
previously published methods(136). Briefly, at three months post-surgery, at which time 
no edema was present in either experimental group, the animals were sensitized by 
applying 300 µL of 2% oxazolone in ethanol to a shaved 1 inch by 1 inch area on the 
abdomen.  Seven days after the initial sensitization, 300 µL of 1.6% oxazolone in a 
solution of acetone and olive oil (4:1) was applied evenly to the entire tail using a 
micropipette, and this procedure was repeated three more times every three days for a 
total of four applications spanning 12 days post-sensitization.  Tail circumference and 
NIR functional measurements were taken before and after oxazolone application. 
Statistical Analysis 
 Tail swelling and lymphatic function metrics were compared between the two 
ligation groups and between each ligation group and the sham group via an unpaired two-
tail t-test with Bonferroni’s multiple comparison correction as appropriate.  The 
correlation between tail swelling and lymphatic transport was calculated using Pearson r 
correlation, and correlation coefficients were tested for significant differences using the 
Fisher r-to-z transformation.  Alpha was equal to 0.05 for all statistical analysis.  
Results 
Single Vessel Ligation Lymphedema Model Produces Differential Swelling Response 
 Tail swelling significantly increased as a result of collecting lymphatic vessel 
ligation compared to the sham group, and ligating the dominant vessel produced 
significantly more swelling than ligation of the non-dominant vessel (Figure 29). 
Dominant ligation swelling peaked at 45% on day 4, while non-dominant ligation 
swelling reached a maximum of 28% swelling on day 14.  Both ligation groups returned 
to normal circumference values on or soon after day 28. The sham control group 
experienced a mild swelling response with peak swelling of 16% on day 4 and full 
resolution by day 14.  
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Figure 29: Tail Swelling Cascade.  Plot of tail swelling of three experimental groups.  Both ligation 
groups produced increased swelling compared to the sham between the 1 week and 3 week time 
points.  The dominant ligation produced significantly increased swelling compared to the 
nondominant ligation at the 2 day and 4 day time points. 
Reductions in Lymphatic Transport Correlate with Disease Progression 
Normalized lymphatic fluorescence transport was significantly reduced in both the 
dominant and non-dominant ligation cases as compared to baseline presurgical values 
and the sham control group (Figure 30).   Specifically, the nondominant group produced 
significantly reduced transport values as compared to baseline at the 1, 2, and 3 week 
periods and compared to the sham group at the 1 and 2 week time points.  The dominant 
group produced significantly reduced transport values relative to baseline at all time 
points and relative to the sham group at the 1, 2, 3 week and 3 month periods.  The sham 
group did not produce significantly altered transport values at any time points. 
Lymphatic transport decreased to a minimum value at the 1-week time point in the 
dominant (8% of healthy transport) and non-dominant cases (35% of healthy transport) 
before beginning to improve at later time points. The dominant ligation also resulted in 
significantly lower transport than the non-dominant ligation at the 1 and 2 week time 
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points.  At the three-month time point transport in the dominant ligation was still 
significantly reduced, while transport in the non-dominant ligation was not significantly 
reduced from baseline healthy values. In both ligation conditions swelling significantly 
correlated with lymphatic function in the negative direction, producing a Pearson r value 
of -0.65 (p<0.0001) while the sham group produced a Pearson r of 0.34, which was not 
significant (Figure 31). Using a Fisher r-to-z transformation, the Pearson coefficients 
between the sham and ligation groups were significantly different (p<0.0001). 
 
Figure 30: Lymphatic fluorescence transport over time.  Plot showing normalized lymphatic 
fluorescence transport for three experimental conditions.  Values are normalized to presurgery 
baseline.  Both ligation groups produced significantly reduced transport compared to the sham at the 
1, 2, and 3 week time points.  The dominant ligation produced significantly reduced transport 
compared to the nondominant ligation at the 1 and 2 week time points. * = significant compared to 





























































































Figure 31: Correlation between tail circumference and lymphatic transport.  Plots of normalized 
lymphatic transport versus normalized tail circumference for the sham group (top left), the two 
ligation groups combined (top right), the dominant ligation group prior to the point of max swelling 
(bottom left), and the dominant ligation group after the point of max swelling (bottom right).  The 
sham group produced a Pearson r of 0.34 while the ligation group produced a Pearson r of -0.65.  
Using a Fisher r-to-z transformation, this difference in correlation coefficients is significant 
(p<0.0001). 
Lymphatic Vasculature Remodels After Lymphedema  
 At the three-month time point swelling in all conditions completely subsided, but 
several factors suggest that the dominant ligation resulted in substantial remodeling in 
lymphatic function compared to the sham control.  Percent positive fluorescent tail area, a 
measure of the relative distribution of lymphatic transport between the collecting vessels 
and the initial capillary network, was significantly increased in the dominant ligation 
(Figure 32).  Emptying rate was not significantly different between the dominant ligation 
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and the sham at the three-month time point.  Effective lymphatic pumping pressure, a 
measure of the pumping capacity of the collecting vessels, was not significantly different 
from the baseline measurement through the day 4 time point but became significantly 
reduced at the three month time point, while the sham group did not produce any 
significant differences in effective pumping pressure at any time point (Figure 32).  
Additionally, in the sham, the dominant lymph node was significantly larger and retained 
significantly more fluorescence than the non-dominant node, but this result was reversed 
in the dominant ligation (Figure 33). 
 
 
Figure 32: Vessel remodeling at the 3 month time point.  Fluorescent tail area was significantly larger 
in the dominant ligation compared to the sham.  Images in the center are representative of transport 
of NIR dye through the tail after injection in the dominant ligation group (top) and the sham group 

































































































































Pumping pressure was reduced in the dominant ligation group at the 3 month time point compared 
to baseline and the sham. 
 
 
Figure 33: Ligation alters node size and retained fluorescence.  Left: Plot showing normalized lymph 
node area ratios between the dominant and nondominant node for the dominant ligation and sham 
groups.  Right: Plot showing normalized lymph node fluorescence between dominant and 
nondominant node for the dominant ligation and sham groups.   
Discussion 
Single Vessel Ligation Model 
 This is the first model known to the authors that allows preservation of an intact 
collecting lymphatic vessel in a lymphedema model and the first model to enable 
functional analysis lymphatic transport during the course of lymphedema.  The timeline 
for tail swelling and eventual recovery followed similar trends reported in the literature 
for full tail ligation models, but the magnitude of swelling in our model was on average 
less than half that reported for the full ligation model(195, 279).  Given that we keep one 
collector fully intact, the magnitude difference in swelling in our model is not surprising 
and may actually serve to test the sensitivity of NIR functional metrics in more mild 
cases of the disease.   
 The tail swelling results also confirmed our hypothesis that ligation of the 
dominant vessel would produce significantly more swelling than ligation of the 
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lymphatic reserve(22, 267). That is, when the dominant vessel is left intact it is better 
able to handle the elevated fluid loads forced upon it after surgery than the nondominant 
vessel.  It is interesting to note that the difference in swelling produced by the dominant 
and nondominant ligation only occurs prior to the 1 week time point, which could suggest 
that remodeling in the matrix and interstitium begins to occur at and beyond this point to 
help alleviate fluid loads, as has been shown to occur in lymphedema models 
previously(164, 253).  It is possible with our experimental setup to track and quantify 
transport through the interstitium and the capillary level lymphatics, and future versions 
of this study with particular emphasis on quantifying transport in this regard could 
provide additional insight to the remodeling cascade. 
 In the spectrum of lymphedema-related swelling, our effect size between the 
dominant and nondominant ligation is relatively small, and it remains unclear what 
implication, if any, these results may have on human lymphedema.  However, these are 
the first results that show a significant difference in outcomes based upon selective 
lymphatic ligation, which could have future implications for surgical planning or targeted 
therapy if the phenomenon is found to be widespread.  Future studies utilizing selective 
vessel ligation in other models would be well warranted, especially models incorporating 
a gravitational load (such as in the limb of a large animal), which may be particularly 
useful in exacerbating the swelling response and highlighting the effects of preferential 
drainage patterns. 
Reductions in Lymphatic Transport and Remodeling 
 In this study we have demonstrated the first direct link between swelling and the 
progressive loss of lymphatic transport function during the lymphedema disease cascade 
in vivo.  The results show that lymphatic transport is significantly reduced after surgery 
in both ligation groups, and the reduction in transport strongly correlates with the level of 
swelling in the ligation groups.  This is consistent with the vast number of studies 
reporting the link between inflammation and the progression of lymphedema; recent data 
from numerous animal and human studies of lymphedema have made it abundantly clear 
that inflammation is perhaps the most important factor in driving lymphedema 
progression, (7, 15, 16, 115, 136, 199, 237, 279) particularly as it relates to the changes 
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that occur in the interstitium. Given that inflammatory cytokines have also been 
demonstrated to adversely affect collecting lymphatic pump function (37, 38, 114, 283), 
it is likely that the consequences of inflammatory driven lymphedema progression not 
only alter the interstitium, but severely compromise pump function and drainage by the 
collectors.  Future work devoted to the application of anti-inflammatories in this model 
may provide valuable insights regarding therapeutic strategies to preserve collecting 
vessel function. 
 It is interesting to note that when the data is divided between the time period prior 
to maximum swelling and after maximum swelling, the correlation only exists in the time 
period prior to maximum swelling.  This presents a potential inconsistency in that 
increased swelling is correlated with reduced lymphatic transport, but decreased swelling 
is not correlated with improved lymphatic transport.  This suggests that the two variables 
are linked only until the swelling reaches its peak, but after that point, residual damage 
and remodeling has occurred such that the relationship is altered, which is supported by 
the observed remodeling and phenotypic changes of excised vessels from human 
lymphedema patients(139).  Such a remodeling event would also be very consistent with 
the observed lymphatic pumping pressure and fluorescent tail area results from this study.  
Lymphatic pumping pressure was not significantly different within the first week, but by 
3 months it was reduced down to less than 10% of the baseline value in the dominant 
ligation group.  The observed increase in fluorescent tail area in the dominant ligation 
group suggests that the interstitium and the initial capillary network were recruited to 
transport a larger percentage of fluid than normal in order to compensate for the chronic 
reduction in lymphatic transport through the collecting vessels, which is a phenomenon 
observed recently in human lymphedema(117). 
 The significant reduction in transport of the dominant group compared to the 
nondominant group further supports the theory of preferential lymphatic drainage 
pathways, at least in the rodent tail.  It is unclear whether the increased swelling 
associated with the dominant group contributed to the reductions in transport or vice 
versa, but it appears obvious that functional differences between the two vessels exist.  
Unfortunately, no data was acquired in this study that can help to establish a mechanism 
or explanation for this relative difference in function between the two collectors, but 
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future studies in this regard would be extremely useful.  For instance, the ability to excise 
collecting vessels from the tail to perform mechanical testing and whole-mount staining, 
while very challenging and approaching the lower limits of the size scale for the 
technique, could help to provide insight as to whether the observed differences are 
potentially due to geometrical and/or structural/compositional variances. 
 Analyzing the packet frequency and packet amplitude results provides additional 
insight into the observed decrease in fluorescence transport of the dominant group.  The 
average packet frequency was reduced only at the 4 day and 1 week time points, while 
the average packet amplitude was reduced at all time points.  This means that the 
majority of the observed reduction in transport was due to reductions in packet amplitude.  
From isolated vessel studies in our lab (not shown), packet amplitude correlates very 
highly with the ejection fraction of the vessel such that larger packet amplitudes occur 
when the ejection fraction is larger.  Since we perform our fluorescence analysis in 
regions of the vessel that are typically dark (vessel constricted), we can further infer that 
observed reductions in packet amplitude are primarily caused by reductions in end 
diastolic diameter, which would be consistent with reports of thickening of the vessel 
wall and decreases in the diameter of the lumen as the remodeling cascade occurs(139). 
 The chronic reduction in lymphatic transport in the dominant ligation group 
through the three-month time point was an unexpected result.  By this time period the 
tissue did not exhibit any signs of swelling, and the ligation scar was no longer visible.  
Based upon visual inspection and volume measurements, the animals did not have 
lymphedema at this point.  However, it is obvious from looking at the transport and 
pumping pressure data that the underlying lymphatic function remained severely 
compromised.  This result is in line with those of Mendez et al. and helps to explain the 
latent lymphatic insufficiency they observed after axillary lymph node dissection in the 
forelimb(136).  It is clear from our data that the lymphatic system sufficiently recovered 
to maintain fluid balance levels, which is why the tissue volume returned to normal.  The 
fact that no significant difference was observed in emptying rate further supports the 
lymphatics accommodate normal fluid loads in the post-lymphedema phase.  The 
reductions in transport and pumping pressure reveal that despite the appearance of normal 
tissue, the vessels have remodeled such that they’ve lost a significant ability to pump, 
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which would explain the inability to handle the elevated fluid loads associated with the 
immune challenge introduced by Mendez and colleagues.  It should be noted that we 
attempted to recreate the results of Mendez by applying oxazolone to the tails after 
lymphedema, but we were unable to achieve a response.  
 Ogata et al. also recently reported substantial phenotypic modulation of smooth 
muscle cells in collecting vessels excised from lymphedema patients such that smooth 
muscle myosin heavy chain isoforms SM1 and SM2 were significantly reduced(161), 
which could explain the observed decline in pumping pressure in our study.  Smooth 
muscle cell content and composition was not investigated in this study, but future work in 
this regard could provide the most meaningful new insights. Alternatively, the reductions 
in transport and pumping pressure could have been caused by changes in valve function 
in response to altered mechanical loading resulting in an inability to maintain 
unidirectional flow and decreasing pumping capacity (49). Under modest mechanical 
loading, the valves of isolated lymphatic vessel chains have been demonstrated to “lock” 
resulting in an inability to pump flow against an adverse pressure gradient (49). Given 
that the behavior of lymphatic valves are highly sensitive to pressure (50) and mutations 
affecting the proper formation of lymphatic valves is one of the most common causes of 
primary lymphedema (132, 143, 167), it is reasonable to suspect non-optimal valve 
function may be contributing to the observed decreases in pumping capacity.  Conducting 
these experiments in a transgenic mouse model without valves or with valve 
deformations, such as the transgenic ephrinB2ΔV/ ΔV model(125), may help to specifically 
elucidate the role of valvular function in lymphedema progression. 
 Analysis of the draining lymph nodes from the dominant ligation and sham 
groups revealed interesting trends regarding lymph transport routes.  In the sham group 
the node draining the dominant vessel was larger and retained more fluorescence than the 
nondominant node, which again supports the theory of differential drainage patterns 
between the two vessels.  Not surprisingly, the lymphatic drainage patterns were altered 
after the dominant ligation to favor the non-dominant node, which drained the fully intact 
vessel.  Interestingly, in the dominant group, the nondominant node was approximately as 
large and retained approximately as much fluorescence as the dominant node of the sham 
group, perhaps suggesting some type of ideal physiological set point.  It is unclear what 
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the ramifications of this change in drainage patterns might be, but it could have 
implications for immune response.  Future investigation regarding the transport of 
immune cells, both through the local tissue environment and to the draining lymph nodes 
may help to provide insight on the link between lymphatic function and immune 
surveillance, especially in the context of reduced lymphatic function. 
 As an additional note, we should also mention that in our study we had two mice 
that had abnormally low baseline lymphatic transport values, and both of these mice 
experienced tail swelling well above the group average.  Unfortunately, both of these 
mice suffered unrelated complications and had to be euthanized early in the time course, 
but it may suggest that research into predisposition of lymphedema would be a 
worthwhile study in this model.  Studies have been reported in the literature citing factors 
potentially leading to a predisposition to lymphedema(17, 18, 218), but this phenomenon 
has not yet been investigated under the control of an animal model.  Given the results of 
our study, we might hypothesize that baseline transport values below a certain threshold 
result in significantly worse disease outcomes or potentially that the baseline difference 
in function between the dominant and nondominant vessels is a predictor of disease 
severity.  Performing this model in aged animals, as has been done in several other 
lymphatic studies(38, 74, 149, 250), may provide a population better suited to study the 
link between the loss of lymphatic function and lymphedema onset and progression. 
Limitations and Future Work 
 Every effort was made to make the ligation and cauterization procedure as 
consistent as possible between animals and between groups, especially attempting to 
ensure that the sham surgeries were as similar in size to those of the vessel ligation 
groups as possible.  We believe we maintained an excellent level of consistency, which 
was aided by only using one person to perform all the surgeries.  However, the ligation 
and cauterization process was not quantified in any way in terms of circumferential 
distance or depth.  It is unclear exactly how the ligation itself affects the subsequent 
outcomes, but this process almost certainly has an affect.  Future efforts to standardize 
this part of the procedure would greatly improve the reproducibility of the results. 
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 The rodent tail model is obviously not a perfect model of human lymphedema for 
a few reasons, perhaps the most glaring of which is the fact that the condition resolves 
itself in the rodent.  This may not be surprising given that the system only needs to 
overcome a gravitational pressure gradient of about 1 cmH2O.  In this model fluid can 
rely upon interstitial flow to a larger degree than may be expected in animals with larger 
gravitational loads, which may limit our ability to isolate the true effects of lymphatic 
failure.  Additionally, this model, by design, is specifically for fatigue-induced 
lymphedema.  While we believe the model provides insights that can be generalized to 
many types of lymphedema and lymphatic failure, it does not specifically address 
potential nuances that may be specific to other causes of lymphedema. 
Conclusion 
 In this study we reported a new lymphedema model that for the first time allows 
assessment of collecting lymphatic function during the lymphedema cascade.  Using the 
model we were able to show the first definitive correlation between swelling and the loss 
of lymphatic function as well as evidence that the vessel remodels in response to the 
swelling such that it loses its pumping capacity.  This model will provide a platform to 
investigate more detailed mechanisms of lymphatic dysfunction associated with 
lymphedema. 
 
CHAPTER 5: CONCLUSION AND FUTURE IMPLICATIONS 
Summary 
 We strongly believe that NIR lymphatic imaging will prove to be an extremely 
useful tool to study the lymphatic vasculature in new and exciting ways and will generate 
insights unobtainable with conventional research techniques.  With that said, the 
methodology remains in an immature state, and we have taken specific steps to advance 
the technique in the physical and physiological aspects.  We performed the first 
engineering analysis of NIR lymphatic imaging, focusing specifically on characterizing 
the limitations of the system with regard to depth penetration and spatial resolution.  We 
demonstrated that fluorophore uptake is dependent on protein concentration and offered 
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an optimal delivery solution of ICG premixed with albumin to maximize SNR in the 
collecting vessels.  Our modulation of the lymphatic system with a dermal nitric oxide 
donor was the first effort to demonstrate that NIR lymphatic function metrics are, indeed, 
sensitive to changes in collecting vessel pumping.  We also provided the first proof that 
packets are directly linked to contractile events in the vessel.  Cumulatively, the first aim 
of this work provided a much-needed assessment of the physical aspects of the technique 
as they relate specifically to imaging and quantifying lymphatic collecting vessel 
function.  The results of this aim have helped to enhance the physiological relevance of 
the metrics and have provided a guide for utilizing the technique specifically in rodent 
research models. 
 The second aim of this work was focused on the physiology of collecting 
lymphatic vessels operating as an organ system.  Specifically, we attempted to address 
the question of how multiple collecting vessels drain a single tissue space.  We were able 
to show that the two collecting trunks draining the rodent tail consistently display 
differential transport function, and we created a new framework for classifying these 
vessels for subsequent analysis by creating the terms “dominant” and “nondominant” 
vessels.  This classification system has proven to be extremely useful in much of our 
subsequent work and has specifically aided our analysis of disease models.  We also 
focused extensive efforts to understanding the limitations of NIR imaging in the context 
of time-course experiments with repeat injections.  Our results helped to clarify a conflict 
in the literature by showing ICG reduces lymphatic function in a time-delayed fashion 
such that repeat imaging sessions produce lower lymphatic function than normal if the 
ICG is not allowed to clear out of the system.  Importantly, we were able to show that a 
commercially available fluorophore limits these time-course effects, which enabled the 
repeat injection procedures necessary for studying lymphedema progression. 
 The final aim of this work represents the crux of the research and provides 
arguably the most impactful results for the field.  We developed the first model of 
lymphedema that allows the assessment of lymphatic collecting vessel function during 
the progression of the disease.  This model has the potential for extensive use by a wide-
range of researchers to probe mechanisms of lymphatic remodeling and pump failure.  
We specifically used the model to provide the first direct correlation increases in swelling 
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and decreases in lymphatic function.  Furthermore, we provided significant evidence that 
fatigue-induced remodeling events occurred in the vessels during the disease cascade 
such that the pumping capacity of the vessels was drastically reduced.  Future work with 
this model will allow the study of specific mechanisms of lymphatic remodeling that lead 
to pump failure, and perhaps more importantly, will allow the investigation of therapeutic 
and prevention strategies to minimize the loss of pump function. 
Limitations 
 There are several limitations to this work that inform the need for future work in 
this area.  Arguably, the largest limitation of our model, and NIR lymphatic imaging in 
general, is the injection of a fluorophore.  The bolus injection increases interstitial fluid 
pressures, the fluorophore itself has effects on the vasculature, and the consistency of the 
injection itself affects uptake.  These are all inherent limitations of the technique that 
cannot be eliminated, but can be managed.  While we’ve attempted to minimize the 
effects of this process on lymphatic function as much as possible by optimizing the 
choice of fluorophore and minimizing the volume of injection, there is no doubt that this 
procedure alters lymphatic function, at least to a small degree. We attempted to make 
every effort to standardize our injection procedure because differences in injection depth 
and angle can dramatically affect fluorophore uptake and resultant NIR functional 
metrics.  We spent considerable time perfecting the technique before performing our 
studies, and we only used one person for injections in a given study to minimize 
variations in technique.  Despite these efforts, variability in the injection was unavoidable 
and contributes to variance in our data.  Future work devoted to the development of 
microneedles specifically optimized for intradermal injection of fluorophores for 
lymphatic imaging would be a monumental improvement to enhance the consistency and 
reproducibility of the technique.  Continued work towards the development of new 
fluorophores specific for lymphatic imaging would also help to eliminate unwanted side-
effects of fluorophore introduction, especially in time-course studies with repeat 
procedures. 
 The second significant limitation of this work centers around the NIR metrics and 
measurement process.  Despite the significant work we devoted to expanding the breadth 
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and utility of existing NIR lymphatic functional metrics, we are still only using a fraction 
of the available data from these procedures.  Perhaps the largest inconsistency in the 
measurement process results from the choice of regions of interest for post-processing 
packet analysis.  We have standardized this procedure internally within our own lab by 
always choosing “dark” regions of the vessel for packet analysis, which provides a 
similar fluorescence profile of packet spikes over time, but much more work could be 
directed towards standardizing and automating this process.  By selecting one or two 
regions of interest along the vessel, we ignore the data from the remaining 80% of the 
collector in the field of view.  Ideally, NIR functional metrics should be calculated using 
as much of the vessel as can fit in the field of view in order to obtain spatially averaged 
transport characteristics along the length of the vessel.  Advanced image processing and 
other computational methods devoted to this effort would almost certainly reveal 
additional insight currently lost in the data sets.  There is also undoubtedly room to 
develop novel metrics beyond those based on packet identification that can more robustly 
assess lymphatic transport and function. 
 An additional limitation is the use of the rodent tail as the anatomic region for our 
model.  The tail provides distinct benefits such as a simple geometry and the ability to 
visualize two collecting vessels simultaneously.  However, it is difficult to translate these 
results directly to other anatomic regions and to other species.  The packet dynamics seen 
in the tail appear to be relatively similar to those reported in rodent and human limbs, 
although a quantitative comparison has not yet been done.  Similarly, the differential 
transport phenomenon between collecting vessels has been reported in rodent limbs, 
which suggests the results of our study can be generalized to other models to at least a 
certain degree. It seems most likely that research developments in the tail model will be 
used mainly address specific questions regarding lymphatic vessel function, which can 
then be tested and validated in other models. 
Additional Hypotheses and Future Work 
 The development of our new single vessel ligation model of lymphedema 
provides a tremendous platform for future work investigating the link between lymphatic 
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function and lymphedema progression.  I have outlined a few targets for future research 
and have provided some potential hypotheses to guide the investigations. 
Therapeutic and Prevention Strategies 
 Given our results showing the correlation between swelling and reduced 
lymphatic function, the extensive research showing the detrimental effects of 
inflammation(7, 15, 16, 115, 136, 199, 237, 279), and literature reports of anti-
inflammatories improving lymphedema outcomes(150), a study investigating the effects 
of anti-inflammatories on collecting vessel function in a lymphedema model would be an 
impactful next step.  Since our results showed that lower levels of peak swelling resulted 
in better long-term collecting vessel transport, I would generally hypothesize that the 
addition of anti-inflammatories to reduce swelling after surgery would help to preserve 
collecting vessel pumping capacity by minimizing remodeling activity within the vessel.  
Of course, to help address these questions, we would first need to better characterize the 
remodeling activity that has occurred in our model with a thorough histological analysis, 
which is a top priority for future work. 
 Other potential therapeutic strategies could potentially include cellular 
regeneration strategies to repair dysfunctional collectors.  Since collecting lymphatic 
vessels are extremely sensitive to their mechanical environment, rebuilding lymphatic 
networks at the cellular may provide a novel regenerative strategy for lymphedema 
treatment.  Recently, Lee et al. have developed a culture system to direct bone marrow 
derived pluripotent stem cells into lymphatic precursor cells.  These precursor cells, 
termed Lymphatic Endothelial Progenitor Cells (LEPCs), are capable of melding into 
new lymphatic vasculature (through lymphatic neovascularization) and spurring new 
lymphatic growth (lymphangiogensis)(110).  To date, it is unclear exactly what effect 
these cells may have on collecting vessel function, but it has been shown that LEPC-
treated mouse tails exhibit increased fluorescence transport through collecting vessels 
(unpublished).  Therefore, I would hypothesize that injection of LEPCs in the 
lymphedema tail model would have either a protective or regenerative effect on 
collecting vessel pump function.  Given the literature regarding the change in coverage 
and composition of smooth muscle cells along vessels from lymphedema patients(161), a 
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similar approach could potentially be taken with the injection of smooth muscle cells to 
potentially restore pumping capacity. 
Vessel Function 
 A phenomenon seen but not explored or quantified in our studies was the 
presence of backflow in our NIR images.  With additional enhancements to our 
processing algorithms, it should be possible to generate a reliable metric of backflow 
within the vessels.  This new data may provide valuable insight regarding the propagation 
of flow, which could potentially be used to assess the functionality of valve segments.  
Initially, I would hypothesize that elevated levels of backflow in baseline measurements 
would be a predictor of worse disease outcomes because it may indicate the vasculature is 
predisposed to fail. 
 Another factor that could be explored as a potential predisposing factor is the 
relative difference in baseline transport between the dominant and nondominant 
collectors.  There are several scenarios that could play out in this regard, but based on our 
results to date, I would hypothesize that normal lymphatic function is characterized by a 
modest increase in transport in the dominant vessel compared to the nondominant vessel, 
and significant deviations in baseline function from this optimal ratio, may indicate a 
predisposition to lymphedema. 
 Finally, one additional factor that could be investigated in our model is the 
presence and quantity of shunting vessels from the ligated vessel to the intact vessel.  
This is a phenomenon that was occasionally observed, but not specifically assessed or 
quantified.  Investigation into the number and functional capacity of these shunt vessels 
could provide interesting data regarding new vessel growth and resultant tissue 
remodeling.  I would hypothesize that larger numbers of functional shunting vessels 
would correlate with reduced levels of swelling because fluid can more effectively be 
transported through the tissue. 
 Overall, we believe the impact of NIR imaging on lymphatic research has only 
just begun and that the technique will provide new opportunities to gain insight about this 
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